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ABSTRACT  
The type II nuclear receptors (NRs) function as heterodimeric transcription factors 
with the retinoid X receptor (RXR) to regulate diverse biological processes in 
response to endogenous ligands and therapeutic drugs. Due to their importance as 
therapeutic targets, the NRs have been extensively studied; however, the rules 
dictating NR transcriptional specificity remain unclear. 
Type II NRs regulate both distinct and overlapping gene programs. DNA-binding 
specificity has been proposed as a primary mechanism dictating how individual NRs 
distinguish their genomic targets. However, many in vivo targets of NRs identified in 
ChIP-seq data lack an identifiable binding site, suggesting that current models of 
DNA binding specificity of the type II NRs are incomplete. A more thorough 
characterization of the DNA binding and gene regulatory specificity of the type II 
NRs will be informative for understanding the role of DNA binding in achieving NR 
transcriptional specificity. NRs function can be altered by ligand binding, post-
  viii 
translational modifications (PTMs), and interactions with other proteins. Therefore, to 
understand how cellular context may alter NR regulatory specificity, analysis of NR 
DNA binding in the presence of different ligands or cell-specific coregulator proteins 
will be informative. 
I used protein binding microarrays (PBMs) to characterize the DNA binding 
preferences of twelve NR:RXRα heterodimers. I find more promiscuous NR DNA 
binding than has been reported, challenging the view that NR binding is defined by 
half-site spacing. I show that NRs bind DNA using two distinct modes, explaining 
widespread half-site binding in vivo. Finally, we show that current models of NR 
DNA binding preferences better reflect binding-site activity rather than binding-site 
affinity. Examining how DNA binding is altered in a cellular context, I find that NR-
DNA binding is significantly altered in the presence of soluble nuclear components, 
such as other transcription factors and transcriptional coregulators. In the presence of 
other nuclear proteins NR DNA binding is less promiscuous, suggesting interactions 
with nuclear proteins can modulate NR DNA binding specificity. Our rich PBM 
dataset and revised NR binding models provide a framework for understanding NR 
specificity and will facilitate more accurate analyses of genomic datasets.  
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CHAPTER ONE: INTRODUCTION 
 
1 General overview 
Nuclear receptors (NRs) are a family of transcription factors (TFs) that are able to 
directly sense environmental changes through ligand binding to regulate gene 
transcription (Everett and Lazar, 2013). NRs are involved in the pathogenesis of a variety 
of human diseases including type II diabetes, atherosclerosis, and cancer (Tenbaum and 
Baniahmad, 1997; Castrillo and Tontonoz, 2004). The ability of NRs to directly bind 
ligand and regulate gene transcription has made them attractive therapeutic targets, and 
many drugs directly target the NRs (Barish and Evans, 2004). Due to the central role NRs 
play in human health, it is important that we work toward a deeper understanding of how 
NRs find their DNA targets and exert their gene regulatory effects. 
1.1 Discovery of the type II NRs 
The discovery of the NRs is rooted in the field of endocrinology, as experiments 
seeking to elucidate the mechanisms of hormone and steroid action led to the 
identification of genes for the estrogen receptor and glucocorticoid receptor (Evans	and	Mangelsdorf,	2014). Isolation of cDNAs for the estrogen, glucocorticoid, and thyroid 
hormone receptors revealed evolutionarily conserved sequences, leading researchers to 
search for other genes following this conserved template (Green	et	al.,	1986;	Hollenberg	et	al.,	1985;	Sap	et	al.,	1986;	Weinberger	et	al.,	1985). NRs were shown to be 
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conserved throughout metazoan evolution (Markov	et	al.,	2017), with 48 NRs encoded 
in humans (Evans	and	Mangelsdorf,	2014). 
NRs discovered based on sequence conservation were initially referred to as 
“orphan receptors”, as their ligands were unknown (Willson and Moore, 2002). The 
ligand-binding domain (LBD) and DNA-binding domain (DBD) of NRs function largely 
independently of one another, which allowed researchers to swap domains of different 
NRs in the search for ligands of these orphan NRs (Giguère et al., 1986; Green and 
Chambon, 1987). Thus, the DNA-binding domain of an NR for which the DNA response 
element was already known could be coupled to the ligand binding domain of an NR with 
an unknown ligand (Green and Chambon, 1987). Cells could then be co-transfected with 
both the cDNA encoding the chimeric NR and a reporter plasmid containing the known 
DNA response element coupled to a reporter gene. Expression of this reporter gene could 
then be used to quantify transcription in response to different ligands, allowing for a rapid 
way to screen a newly discovered NR against a panel of candidate ligands (Giguère et al., 
1986; Levin et al., 1992). This reverse endocrinology approach identified 9-cis retinoic as 
the ligand for the retinoid X receptor (RXR) (Heyman et al., 1992; Levin et al., 1992; 
Mangelsdorf et al., 1990). These screens also revealed that RXR was capable of 
functioning as a heterodimer with a protein that responded to chemicals known to cause 
proliferation of peroxisomes, leading to the subsequent identification of another NR, the 
peroxisome-proliferator activated receptor (PPAR) (Issemann and Green, 1990; Kliewer 
et al., 1992). 
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The ability of RXR to function as a heterodimer led to the identification of many 
other NR partners of RXR, including the liver x receptors (LXRs), retinoic acid receptors 
(RARs), farnesoid X receptor (FXR), vitamin D receptor (VDR), pregnane X receptor 
(PXR), constitutive androstane receptor (CAR), and thyroid hormone receptors (THRs) 
(Fig. 1.1) (Evans and Mangelsdorf, 2014; Kliewer et al., 1992; Zhang et al., 1992). NRs 
that function as heterodimers with RXR became known as the type II NRs. Many type II 
NRs are key regulators of metabolic homeostasis and their endogenous ligands are 
metabolic derivatives, thus directly coupling changes in cellular nutrient availability to 
regulation of metabolic pathways (Evans and Mangelsdorf, 2014). 
 
Figure 1.1 Type II nuclear receptors 
The type II nuclear receptors that can dimerize with RXRa are shown. All the NRs examined 
within this thesis are shown in black. 
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Other type II NRs regulate development (RARs), general homeostasis (VDR), 
basal metabolic rate (THR), and protection from xenobiotics (CAR and PXR) (Evans and 
Mangelsdorf, 2014).  
 1.2 Conserved Structure of Nuclear Receptors 
 
Figure 1.2: Structural organization of the nuclear receptors.  
Structural organization of the NRs is shown in a 1D schematic alongside the corresponding 3D 
structure. Shown are the N-terminal domain containing the activating function-1 region (A/B 
region), the DNA binding domain (C region), the hinge (D region), ligand binding domain (E 
region), and C-terminal domain containing the activating function-2 region (F region). Regions 
shown as dotted lines within the crystal structure are flexible and could not be structurally 
resolved. Figure obtained from Wikipedia and is in the public domain. 
 
NRs share a modular, conserved structure (Fig. 1.2) (Glass and Ogawa, 2005; 
Green and Chambon, 1987). NR domains include the N-terminal activation function 1 
region (AF-1), which regulates transcription in the absence of ligand; the DBD composed 
of two C4 zinc fingers that result in sequence-specific binding to DNA; the hinge region, 
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which serves as a flexible linker connecting the DBD to the LBD; and the C-terminal 
LBD, which contains the ligand-dependent activation function 2 region (AF-2) (Jin and 
Li, 2010).  
 1.3 DNA binding preferences of the type II NRs  
NRs rely on sequence-specific DNA binding to regulate target genes. Early 
experiments seeking to establish the DNA sequences recognized by type II NRs utilized 
electrophoretic mobility shift assays (EMSAs) to test sequences from promoters of 
ligand-responsive genes for each NR (IJpenberg et al., 1997; Kurokawa et al., 1993; 
Meier et al., 1993; Perlmann et al., 1993; Xie et al., 2000). The majority of response 
elements identified were variations of two direct repeats (DRs) of the sequence 5’-
RGKTCA-3’ (T, G, C, and A represent the standard DNA bases, R can be either A or G, 
and K can be either G or T) with a variable length between the two half-sites, often 
referred to as DR0-5 (Evans and Mangelsdorf, 2014; IJpenberg et al., 1997). The 3-4-5 
rule, which stated that DR spacer length is a primary determinant of NR specificity, 
became the prevailing paradigm for NR target specificity (Evans and Mangelsdorf, 2014; 
Perlmann et al., 1993; Umesono et al., 1991). However, subsequent experiments revealed 
that there were exceptions to this simple paradigm, as many NRs share the same spacer 
preferences, and a single NR can bind to DRs with different spacer lengths (Evans and 
Mangelsdorf, 2014; Perlmann et al., 1993). Additionally, the DNA sequences directly 
flanking the DRs have also been demonstrated to impart binding specificity for PPARg, 
THR, and RAR (Juge-Aubry et al., 1997; Phan et al., 2010).  
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The DNA binding preferences of the NRs were turned into position-weight 
matrices (PWMs), a commonly used mathematical model that describes the log-
likelihood of a TF binding to any DNA sequence, which were used to predict NR binding 
in the genome (Stormo and Zhao, 2010). With the onset of genome-wide occupancy 
studies, it has become clear that a large portion of NR binding cannot be explained by 
existing PWMs (Boergesen et al., 2012; Everett and Lazar, 2013). For instance, binding 
sites as identified by these PWMs are found in only 45-70% of the genomic regions 
where PPARγ binding is detected in ChIP-seq, suggesting that divergent sequences are 
capable of mediating binding or that PPARγ is being indirectly recruited to DNA by other 
factors (Boergesen et al., 2012; Everett and Lazar, 2013; Lefterova et al., 2008; 2010; 
Nielsen et al., 2008). Attempts to computationally identify divergent binding sites within 
these existing PPARγ ChIP-seq datasets have yielded a few new candidate sequences, but 
no validation has been performed for these sites (Lemay and Hwang, 2006). Additionally, 
even when these new models are included, a large portion of PPARγ binding events 
remain unexplained (Lemay and Hwang, 2006). These analyses support the idea that 
divergent binding sites for NRs exist and that utilizing a high-throughput approach to 
characterize binding, such as the PBM approach utilized in Chapter 2, are necessary for 
future genomic analyses of the NRs.  
1.4 Nuclear receptor function 
As the innate ability of NRs to bind ligand has made them attractive therapeutic 
targets, the ligands and LBDs of NRs have been extensively studied (Choudhary and 
Malek, 2016; Heemers and Tindall, 2010; Nomiyama and Bruemmer, 2008). Ligand-
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binding induces a conformational change in the LBD of NRs that alters the structure of 
these proteins, allowing for recruitment of coactivators through a conserved LxxLL motif 
found in a variety of coregulators (McInerney	et	al.,	1998). Corepressors are recruited 
through a similar LxxH/IIxxxI/L motif that interacts with NRs in a region overlapping the 
region used to interact with coactivators, thus NR recruitment of coactivators or 
corepressors is largely mutually exclusive (Hu and Lazar, 1999; Perissi et al., 1999; 
Perissi and Rosenfeld, 2005).  
Initial characterization of NR signaling suggested that in the absence of ligand the 
type II NRs are pre-bound to DNA and function as repressive TFs, interacting with ATP-
dependent chromatin remodelers, histone deacetylases, and histone demethylases to 
create a repressive chromatin environment (Everett and Lazar, 2013). In this model, 
ligand binding leads to the exchange of corepressors for coactivators, that in turn promote 
a permissive chromatin environment resulting in upregulation of transcription (Perissi 
and Rosenfeld, 2005). While these initial insights into NR function were attractive for 
their simplicity, recent research has demonstrated that NR function is more nuanced than 
initially thought, with DNA response element sequence, ligands, and post-translational 
modifications capable of altering NR function (discussed in detail in sections 1.6 and 
1.8). 
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1.5 Structural perspectives on NR function  
Crystal structures of isolated NR DBDs and LBDs gave initial insights into the 
structural elements governing NR 
function (Gampe et al., 2000; Schwabe et 
al., 1993; Uppenberg et al., 1998; Wurtz 
et al., 1996). PPARγ:RXRα was the first 
full-length NR crystal structure to be 
obtained and revealed extensive cross-
domain interactions that impact NR 
function, which could not be appreciated 
in earlier structures of isolated NR domains 
(Chandra et al., 2008). This full-length 
PPARγ:RXRα crystal structure, obtained in 
the presence of both DNA and coactivator 
peptides, gave insight into the different domains of the heterodimer that are involved in 
DNA recognition (Chandra et al., 2008) It demonstrated that the first zinc finger of each 
receptor’s DBD interacts extensively with the major groove of the DNA response 
element. Interestingly, it revealed that domains outside of the DBDs also interact directly 
with DNA (Fig. 1.3). The 5’ flanking region of the first half-site of the DR is contacted 
extensively by the hinge region of PPARγ, which may explain the polarity observed in 
PPARγ:RXRα binding. In all instances where it has been explored, PPARγ occupies the 
5’ half-site, and the sequence of the 5’ flanking region has been shown to influence 
Figure 1.3 Crystal structure of DBDs of 
PPARg:RXRa bound to DNA.  
 a DNA sequence of DR is shown, including 
the 5’ extension site. b Crystal structure of 
PPARg:RXRa DBDs bound to DNA probe 
from a is shown. Figure adapted from 
(Chandra et al., 2008). 
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binding affinity (IJpenberg et al., 1997). This observed polarity is in contrast to other 
RXR heterodimers, wherein RXR occupies the 5’ half-site (Zechel et al., 1994). 
Additionally, the crystal structure revealed that the DBD-DBD interaction gained in the 
presence of DNA are facilitated by contact with the spacing nucleotide that shield the 
hydrophobic amino acids of the contact from interaction with solvent (Chandra et al., 
2008).  
The PPARγ:RXRα crystal 
structure was also elucidating 
because it revealed how structural 
changes in one domain of the 
heterodimer can induce structural 
changes that propagate to other 
domains (Fig. 1.4) (Chandra et al., 
2008). In the absence of both ligand 
and DNA, heterodimerization of 
PPARγ:RXRα occurs only through 
the LBD. Upon DNA binding, two new cross-receptor interactions are made including a 
DBD-DBD contact and a contact between the LBD of PPARγ and the C-terminal 
extension of the DBD of RXRα. This DNA-induced alteration in NR heterodimer 
structure was further supported by studies of PPAR using hydrogen/deuterium exchange 
coupled to mass spectrometry and small-angle x-ray scattering (Bernardes et al., 2012), 
as well as by subsequent full-length crystal structures for VDR:RXR and HNF4a (Lou et 
Figure 1.4 Crystal structure of full-length 
PPARγ:RXRα bound to DNA.  
Figure adapted from (Chandra et al., 2008). 
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al., 2014). These extensive cross-domain interactions taken together with the conserved 
structure of the nuclear receptor family may help explain experimental observations that 
the DNA binding site sequence can allosterically regulate NR function, by altering the 
structure of the NR and impacting coregulator assembly (discussed in detail in sections 
1.6 and 1.8) (Hall et al., 2002; Meijsing et al., 2009).  
1.6 DNA sequence as an allosteric regulator of NR function 
In the classical model of NR function, unliganded NRs act as transcriptional 
repressors, and ligand binding acts as a molecular switch allowing NRs to become 
transcriptional activators (Everett and Lazar, 2013). However, recent high-throughput 
techniques such as RNA-seq and massively parallel reporter assays have shown that 
while this model holds true at many loci, liganded NRs also mediate other types of 
transcriptional regulation, including repression (Everett and Lazar, 2013; Schöne et al., 
2016; 2018).  
Part of the locus-specific function of NRs may be attributed to the significant 
structural changes that occur upon binding to different DNA sequences, which alter the 
exposed surfaces available for interaction with coregulators (Bernardes et al., 2012; 
Chandra et al., 2008; Lou et al., 2014). Studies of the estrogen receptor (ER), 
glucocorticoid receptor (GR), and VDR have demonstrated that response element 
sequence allosterically regulates NR function by influencing the composition of 
complexes recruited to different DNA sequences (Koszewski et al., 2000; Meijsing et al., 
2009; Schöne et al., 2016). Negative response elements that lead to ligand-induced 
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transcriptional repression have been identified for GR and VDR (Koszewski et al., 2000; 
Meijsing et al., 2009; Surjit et al., 2011), and both receptors make different DNA contacts 
on these negative response elements (Koszewski et al., 2000; Meijsing et al., 2009).  
While the ability of DNA sequence to allosterically regulate NR function has been 
studied at small-scale for some NRs, most NRs have not yet been examined and high-
throughput approaches are underutilized. The finding that many NRs are allosterically 
regulated by DNA, coupled with the conserved nature of NR structure, necessitates the 
study of allosteric regulation of NRs that is described in Chapter 3.  
1.7 Nuclear receptors coregulators 
Coregulators are key mediators of transcriptional regulation for nearly all TFs, 
including the NRs (Lonard and O'Malley, 2007). Over 400 coregulators of NRs have 
been identified (Dasgupta et al., 2014; Lonard and O'Malley, 2007). Coregulators possess 
a variety of functions with unique regulatory consequences, including histone deacetylase 
activity (HDAC), histone acetyltransferase (HAT) activity, histone methyltransferase 
(HMT) activity, methyltransferase activity, demethylase activity, and ATP-dependent 
chromatin remodeling activity, all of which impact chromatin state and gene activity 
(Dasgupta et al., 2014; Lonard and O'Malley, 2007; Millard et al., 2013). Coregulators, 
including the steroid receptor coactivators (SRCs), also serve as scaffold proteins to 
allow for recruitment and assembly of larger transcriptional complexes, including 
recruitment of the mediator complex and other core transcriptional machinery to impact 
many stages of transcription (Viswakarma et al., 2010).  
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Coregulators are classified as either coactivators or corepressors based on their 
ability to activate or repress transcription, respectively. Modulation of coregulator 
activity is partially dictated by post-translational modifications (PTMs), including 
acetylation, phosphorylation, sumoylation, and ubiquitination (Millard et al., 2013). 
Additionally, coregulator activity is complex and a single coregulator can possess both 
coactivator and corepressor functions, with the switch between these functions often 
being regulated by PTMs (Poulard et al., 2017; Purcell et al., 2011). These PTMs serve as 
a regulatory interface allowing for integration of upstream signaling cascades, which alter 
the function of coregulators ultimately leading to changes in transcriptional regulation. 
Additionally, differential expression of coregulators influences cell-type specific NR 
function (Dasgupta et al., 2014).  
Considering their diverse capabilities, assembly of different coactivator 
complexes results in differential gene regulation at distinct NR target genes, necessitating 
an understanding of the molecular determinants of site-specific recruitment of 
coactivators; this will be carried out in Chapter 3. 
1.8 PPARγ and Adipocytes: 
PPARg is highly expressed in adipocytes and is central to adipocyte function, as it 
is necessary for maintenance of the adipocyte phenotype and is sufficient to convert 
fibroblast-like pre-adipocytes into mature adipocytes (Barak et al., 1999; Rosen et al., 
1999). Mice deficient in PPARg lack adipocytes (Barak et al., 1999; Rosen et al., 1999). 
There are three main categories of adipocytes: white adipocytes that store fat; brown 
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adipocytes that are thermogenic; and brite/beige adipocytes that have an intermediate 
phenotype between white and brown adipocytes (Giralt and Villarroya, 2013). 
Differences in function between white, brown, and brite/beige adipocytes are partially 
due to differential PPARg-mediated transcriptional programs (Villanueva et al., 2013).  
Ligands are key modulators of PPARγ function in adipocytes, impacting both 
protein conformation and transcriptional regulation (Chrisman et al., 2018). Changes in 
PPARg conformation alter the surfaces of the protein that are available for PTMs and 
coregulator assembly (Chrisman et al., 2018; Villanueva et al., 2013). In turn, PTMs 
impact the set of genes that are regulated by PPARγ (Choi et al., 2010; 2011; Farmer, 
2008). For instance, Sirt1-mediated acetylation of PPARγ (Qiang et al., 2012) and cdk5-
mediated phosphorylation of PPARγ (Choi et al., 2011) lead to regulation of distinct gene 
programs. The ligand-dependent alteration in PPARγ PTMs and subsequent impact on 
transcriptional regulation have been clearly demonstrated; however, it remains unclear 
why transcription is only impacted by at specific loci in the genome.  
Exogenous ligands of PPARγ have distinct impacts on metabolic function. 
Environmental pollutants can also act as ligands for the NRs, including PPARγ (Hurst 
and Waxman, 2003; Maloney and Waxman, 1999) and are often endocrine disruptors that 
impair human health (Balaguer et al., 2017; Delfosse et al., 2014). Triphenyl phosphate 
(TPhP), an organophosphate often used as a flame retardant treatment for furniture, was 
recently identified as an environmental ligand of PPARγ (Wang et al., 2018a). Unlike 
rosiglitazone, TPhP has an adverse effect on insulin sensitivity in male mice, leading to 
impaired glucose homeostasis (Wang et al., 2018a). In both bone marrow stromal cells 
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and 3T3-L1 pre-adipocytes, exposure to TPhP leads to increased adipogenesis (Pillai et 
al., 2014; Tung et al., 2017). Ongoing studies are investigating the mechanisms 
underlying the distinct transcriptional programs elicited by environmental ligands of the 
NRs. In Chapter 3, we examine the DNA binding of NRs and coactivator recruitment 
from 3T3-L1 adipocyte nuclear lysate. Given the many vital cellular processes that 
PPARγ regulates, it is essential that we work toward understanding locus-specific 
function of PPARγ. Due to the central role of PPARγ in adipocytes, they are an ideal cell 
type in which to carry out these analyses. 
1.9 Thesis Rationale: 
Our current understanding of NR-DNA binding specificity is lacking, as current 
models do not distinguish the unique repertoire of target genes selected by NRs, and 
binding to many in vivo targets remains poorly explained by current models of DNA 
binding. Additionally, locus-specific function of NRs remains poorly understood.  
In Chapter 2 of this thesis, we describe the use of custom-designed protein 
binding microarrays (PBMs) to comprehensively characterize the DNA binding 
preferences of twelve different type II nuclear receptors. Our analyses do not support the 
established target DNA site spacing preferences for type II NRs. We demonstrate that the 
canonically reported spacing preferences describe functional NR binding rather than 
binding affinity of purified NRs. Our modeling of NR binding motifs, based on a single-
nucleotide variant (SNV) approach, also reveals that functional NR binding may be 
partially determined by the binding mode utilized by NRs. 
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In Chapter 3 of this thesis, we use the nuclear extract protein binding microarray 
(nextPBM) platform to examine (1) the DNA binding specificity of NRs in a cellular 
context and (2) co-regulator recruitment from nuclear lysates. We find that the DNA 
binding preferences of PPARg are changed in a cellular context. We also demonstrate 
that steroid receptor coactivator 1 (SRC1), a NR coregulator, shows strong DNA 
sequence-dependent recruitment. 
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CHAPTER TWO: DNA BINDING SPECIFICITY OF PURIFIED TYPE II NRs  
The work presented in this chapter was performed by me and Jessica Keenan, 
resulting in a co-first author publication (Penvose et al., 2019). All experimental work 
(cloning, protein expression and purification, PBMs, and reporter experiments) within 
this chapter were performed by me. The seed sequences used on the custom PBM used 
for the experiments in this chapter were chosen by me. Jessica Keenan performed the 
computational portions to create the fully expanded probe set for this PBM design. 
Author contributions to data acquisition and analyses performed in this chapter are made 
in the figure legends.  
2.1 Abstract 
The type II nuclear receptors (NRs) function as heterodimeric transcription factors 
with the retinoid X receptor (RXR) to regulate diverse biological processes in response to 
endogenous ligands and therapeutic drugs. DNA-binding specificity has been proposed as 
a primary mechanism for NR gene regulatory specificity. In this chapter, I used protein-
binding microarrays (PBMs) to comprehensively analyze the DNA binding of 12 
NR:RXRa dimers. I found more promiscuous NR-DNA binding than has been reported, 
challenging the view that NR binding specificity is defined solely by half-site spacing. I 
show that NRs bind DNA using two distinct modes, explaining widespread NR binding 
to half-sites in vivo. Finally, using reporter assays that I performed and genomic 
enrichment analyses performed by Jessica Keenan using the models I generated from the 
PBM experiments, we demonstrate that the current models of NR specificity better reflect 
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binding-site activity rather than binding-site affinity. Our rich dataset and revised NR 
binding models provide a framework for understanding NR regulatory specificity and 
will facilitate more accurate analyses of genomic datasets. 
2.2 Introduction. 
The type II nuclear receptors (hereafter simply NRs) are ligand-activated 
transcription factors (TFs) that control diverse cellular processes including development, 
metabolism, and inflammation (de Aguiar Vallim et al., 2013; Evans and Mangelsdorf, 
2014). NRs include peroxisome-proliferator activated receptor (PPAR), liver x receptor 
(LXR), retinoic acid receptor (RAR), farnesoid x receptor (FXR), pregnane x receptor 
(PXR), thyroid hormone receptor (THR), and vitamin D receptor (VDR) (Evans and 
Mangelsdorf, 2014; Kliewer et al., 1999). NRs function as heterodimers with the 
common partner, the retinoid x receptor (RXR). Individual NR heterodimers can regulate 
distinct gene programs (Calkin and Tontonoz, 2012); however, the current models of NR-
DNA binding specificity are insufficient to fully explain NR-specific gene regulation. 
NRs bind the sequence 5’-RGKTCA-3’ organized as direct repeats with a variable 
length spacer of 0–5 base pairs (bp) (DR0-DR5, Fig. 2.1a) (Claessens and Gewirth, 2004; 
Cotnoir-White et al., 2011; Weikum et al., 2018). Current models propose that DR spacer 
length is a key determinant of DNA-binding specificity for NRs (Cotnoir-White et al., 
2011; Evans and Mangelsdorf, 2014; Kurokawa et al., 1993; Mader et al., 1993; 
Perlmann et al., 1993). For example, PPAR:RXR dimers prefer binding to DR1 elements, 
whereas LXR:RXR dimers prefer DR4 elements (Fig. 2.1b). However, there are more 
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NRs than available spacer lengths; therefore, either DRs are bound by multiple NRs, 
which presents a problem for achieving NR-specific gene activation, or there are 
additional determinants of NR-binding specificity beyond DR spacer length. 
Differences in DNA-binding specificity for each NR would provide a mechanism 
for NRs to regulate distinct target genes in vivo. Genome-wide chromatin 
immunoprecipitation followed by sequencing (ChIP-seq) studies have confirmed known 
NR preferences for particular DR spacer lengths, and have reinforced the connection 
between in vitro and in vivo binding (Boergesen et al., 2012; Chatagnon et al., 2015; Le 
Zhan et al., 2014; Lefterova et al., 2010; Rastinejad et al., 2013; Savic et al., 2016; Soccio 
et al., 2015). However, these studies have also revealed limitations to current models of 
NR-DNA binding. For example, PPARγ and LXRα regulate distinct yet overlapping gene 
programs but do not share a DR element to explain their many common genomic targets 
(Boergesen et al., 2012; Savic et al., 2016). Additionally, many genomic regions that are 
bound in vivo lack an identifiable binding site for the NR being investigated (e.g., 90–
96% for PPARγ and LXR) (Boergesen et al., 2012). Together, these observations suggest 
that current models of NR-DNA-binding specificity are incomplete. 
To address the need for revised models of NR binding, we use protein-binding 
microarrays (PBMs) to compare the binding of 12 NR:RXRα dimers to thousands of 
DNA sequences. To examine DR spacer preferences, we assay NR binding at all spacer 
lengths (DR0-DR5). We identify both NR-shared and NR-specific binding features in our 
dataset, and discuss implications for NR-signaling specificity. By integrating PBM and 
ChIP-seq datasets, we examine the relationship between in vitro and in vivo binding. We 
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address the role of activity versus affinity in current models of NR specificity by 
integrating PBM data with reporter gene experiments. Our results demonstrate the 
limitations of DR spacer length for defining NR specificity and of DNA binding affinity 
for predicting functional binding events. 
2.3 Results 
2.3.1 Characterizing NR heterodimer binding with PBMs 
I used PBMs to characterize the DNA binding of 12 distinct RXR heterodimers 
(hereafter NRs). PBMs are double-stranded DNA microarrays that enable the high-
throughput study of protein-DNA binding (Berger et al., 2006a). To characterize both 
DNA-base and DR-spacing preferences, I measured NR binding to over 1600 unique 
sequences at each of six DR spacer lengths (DR0-DR5). For each DR spacer length, I 
measured NR binding to 24 starting sequences, which I refer to as seed sequences (Fig. 
2.1c). Seed sequences were generated by combining different half-site sequences 
exhibiting a range of degeneracy from the consensus 5’-RGKTCA-3’ (seed sequence 
selection is detailed in section 2.5.2). Most seed sequences contain two distinct half-site 
sequences. To assay NR binding specificity for each seed sequence I also measured 
binding to all possible single-nucleotide variants (SNVs), with each SNV included as a 
separate probe on the PBM (Fig. 2.1c). This SNV-based approach allows us to generate a 
binding logo (i.e., energy matrix or position-weight matrix (PWM)) for each individual 
seed sequence by measuring the impact on binding caused by perturbation at each base 
position (Fig. 2.1c, Methods). To capture binding preferences for DR spacer and flank 
sequences, we included SNVs across the spacer sequence and for the five nucleotides 
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upstream and downstream of the DR. Using this comprehensive SNV-type PBM design, 
we characterized the DNA-base and DR-spacing preferences of the NRs. 
PBM experiments for NR heterodimers (NR:RXRα) were performed by 
combining purified RXRα with purified samples of each partner NR. Hereafter, we refer 
to NR:RXRα heterodimers simply by the NR partner, and RXRα:RXRα homodimers as 
RXRα, unless otherwise stated. Most NRs do not bind DNA with high affinity as 
homodimers; therefore, proteins were combined at a 3:1 NR:RXRα ratio to force RXRα 
heterodimer formation (exceptions indicated in Table 2.1). To ensure heterodimer 
binding, I required that the binding results agreed when performed using antibodies for 
both RXRα and the non-RXRα partner. Binding profiles using separate antibodies 
showed strong correlation, demonstrating that both protein partners were bound to each 
DNA probe at similar levels (Fig. 2.1d, R2 of antibody replicates in Table 2.1). Binding 
of homodimers were not correlated with each other, nor with the heterodimers 
(Supplementary Fig. 2.1), further demonstrating heterodimer binding. To quantify 
binding specificity, PBM fluorescence values were converted into z-scores using a set of 
500 random genomic background sequences (Fig. 2.1e). Validated PPARγ binding sites 
score significantly above background, down to a z-score of 1.5 (Fig. 2.1e). We set a more 
stringent z-score cutoff of 3.0 to define the affinity cutoff for functional binding sites. A 
DR1 DNA binding logo generated for PPARγ agrees well with known logos from ChIP-
seq (Fig. 2.1f), demonstrating the sensitivity of our assay. To validate our PBM results 
with an orthogonal approach, I performed competition electrophoretic-mobility shift 
assays (EMSAs) to measure the relative binding affinity of PPARγ:RXRα to DNA 
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sequences bound over a wide range of PBM z-scores (Fig. 2.1g, Supplementary Fig. 2.2). 
I found strong agreement between the relative binding affinities derived using both 
approaches (R2 = 0.93). The protein samples used for these experiments were produced in 
bacterial or insect cells; however, our ability to capture known NR-binding specificity 
suggests our data reflect native mammalian dimer-binding specificity. These results 
demonstrate that our PBMs accurately capture sequence-specific binding of NR 
heterodimers. 
2.3.2 NRs bind promiscuously to most DR spacings 
To understand NR-signaling specificity, studies have examined the DNA-binding 
differences between NRs (summarized in Fig. 2.1b, Table 2.2 and Supplementary Data 3 
from (Penvose et al., 2019)) (Cotnoir-White et al., 2011; Evans and Mangelsdorf, 2014; 
Juge-Aubry et al., 1997; Mader et al., 1993; Näär et al., 1991). A prevailing view is that 
NRs are distinguished by their preference for DR sites with specific half-site spacing) 
(Cotnoir-White et al., 2011; Evans and Mangelsdorf, 2014; Juge-Aubry et al., 1997; 
Mader et al., 1993; Näär et al., 1991; Perlmann et al., 1993; Zechel et al., 1994).; 
however, individual NRs are functional on DR sites with various spacings (Katz et al., 
1995; Kurokawa et al., 1993; Miyamoto et al., 1997),. Therefore, for each NR we 
examined which DR spacings were bound with sufficient affinity such that they might be 
functional in vivo. 
To visualize the NR-binding landscape, I generated a DNA-binding logo from 
high-scoring seeds at each DR spacing (Fig. 2.2). Strikingly, for all NRs I was to able 
generate DNA-binding logos at nearly every DR spacing, demonstrating broader binding 
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preferences than previously reported. While previous reports have shown strong 
preferences for DRs of certain spacer lengths, the ability to generate logos at alternative 
spacer lengths suggests that binding can occur at other spacer lengths (discussed in more 
detail in 2.3.5). Comparing our logos with published DR binding preferences (Fig. 2.1b), 
I found high-affinity binding for many NRs at new DR spacings. The binding logos for 
all NRs exhibit the canonical 5’-RGKTCA-3’ sequence preferences in each half-site and 
agree with base preferences reported by other methods (Isakova et al., 2017; Kulakovskiy 
et al., 2013). The logo similarity demonstrates broad conservation in NR-binding 
specificity; however, NR-specific preferences are also present. For example, PPARγ 
prefers an AT-rich sequence 5’ of the first half-site of a DR (Juge-Aubry et al., 1997) and 
my PPARγ logo shows this extended footprint (Figs. 2.1f, 2.2). Overall, my data reveals 
that all NR heterodimers can bind to sites with variable DR spacings and with highly 
overlapping base specificities. 
2.3.3 All type II NRs can bind DNA using a half-site mode 
I found that all NRs can bind with high affinity to half-sites (Fig. 2.2, final two 
columns). For all NRs, I obtain both 5’- and 3’-half-site logos, with the exception of 
PPARγ for which I only find clear 5’-half-site binding (Fig. 2.2). Half-site logos indicate 
that NR binding is only perturbed by SNVs introduced into one half-site of a DR, and 
that the SNVs introduced in the other half-site cause no changes in affinity. To illustrate, 
I show the impact of SNVs on LXRα heterodimer binding to seed sequences with 
different binding modes (Fig. 2.3a-c, Supplementary Fig.2.3). Critically, my data agrees 
for PBMs probed with antibodies against either dimer member; therefore, half-sites are 
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bound by NR heterodimers and are not a result of monomer binding. The presence of 
both full-site and half-site logos suggests that NRs can engage with DNA in two binding 
modes: (1) full-site mode where the NR engages with both half-sites and (2) half-site 
mode where the NR engages with a single half-site (either 5’ or 3’) (Fig. 2.3a). 
To ensure that the widespread half-site binding was not a result of our 
methodology, we performed several analyses. First, we tested whether half-site binding 
was due to the orientation of the NR-binding site within the PBM probe with respect to 
the microarray slide. We find that regardless of orientation of the probe, binding mode is 
maintained (Supplementary Fig. 2.4). Second, I performed PBM experiments at 
successively lower concentrations to test whether half-site binding is affected by protein 
concentration and find nearly identical DNA binding logos at all concentrations 
(Supplementary Fig. 2.5). Finally, I used EMSA experiments to test the impact of base 
mutations on a DNA site bound in half-site mode (Fig. 2.1g, sequences P3, P3 5’-Abl, P3 
3’-Abl). Critically, the 5’ half-site mode of PPARγ:RXRα determined by PBM is 
corroborated by EMSA experiments (i.e., 5’ half-site ablation greatly reduced binding 
whereas 3’ half-site ablation only modestly affected binding) (Fig. 2.1g, Supplementary 
Fig. 2.2). These results demonstrate that PBM-derived binding modes accurately 
represent native NR-binding modes. 
NRs are known to bind half-sites (Fig. 2.1b), though half-sites have primarily 
been identified in ChIP-seq data and not through direct binding assays. My analysis 
clarifies that NR heterodimers can bind half-sites, and can engage in a half-site mode 
even on canonical DR sites composed of two good half-sites (i.e., both half-sites score 
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well using PWMs). For example, logos generated for a near-consensus DR1 seed 
sequence that scores highly by DR1 PWMs reveal both full- and half-site binding modes 
(Fig. 2.3d). While all NRs bind this site with high-affinity (z-scores are shown), only 
PPARγ binds in a full-site mode, while other NRs bind in half-site modes that are nearly 
identical to one another. This shows that binding mode can vary for different NRs on the 
same DNA site, and that throughout the genome NR-binding to DR sites may in fact be 
mediated through a half-site binding mode. 
2.3.4 Role of monomers in half-site binding 
To examine the contribution of each protein within an NR heterodimer to DNA 
binding, I created DNA-binding domain mutants (DBDmut) of RXRα and PPARγ. Two 
residues within zinc finger 1 of RXRα and PPARγ that make base-specific contact with 
DNA were mutated to alanines (K156A and R161A; and K132A and R137A, 
respectively, Fig. 2.3e) (Chandra et al., 2008). Binding of PPARγ:RXRα-DBDmut is 
highly correlated using either anti-RXRα or anti-PPARγ antibodies (R2 of antibody 
replicates given in Table 2.1), showing that all DNA sites are bound by the mutant as a 
heterodimer. For PPARγ-DBDmut:RXRα, PBMs performed using an anti-RXR antibody 
are dominated by RXR homodimer signal, therefore binding of PPARγ-DBDmut:RXRα 
was determined using only the anti-PPARγ antibody. RXRα homodimer binding was not 
observed in wild-type heterodimer experiments (see above). All DBD mutant proteins 
were produced by IVT and PBM data for IVT-produced wild-type dimers agree with 
experiments using purified proteins, demonstrating that IVT proteins form heterodimers 
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and function in DNA-binding assays similarly to purified proteins (model curations can 
be found in Supplementary Data 4 of (Penvose et al., 2019). 
To confirm that these mutations abrogated DNA interactions, I examined the 
binding of mutant homodimers using PBMs. The mutant RXRα (RXRα-DBDmut) bound 
no sequences with z-score > 3.0 (as compared to a max z-score of 7.0 for PPARγ:RXRα-
DBDmut described below), demonstrating an abrogation of sequence-specific DNA 
binding. The mutant PPARγ (PPARγ-DBDmut) showed binding with z-score > 3.0 to 
only five seed sequences. Previous experiments have shown residual DNA-binding 
activity for PPARγ DBD mutants (Temple et al., 2005); therefore, I chose to disregard 
these five sequences from further analysis of the PPARγ-DBDmut:RXRα heterodimer 
experiments. 
I first examined mutant heterodimer binding to sequences that PPARγ:RXRα 
binds in full-site mode. As expected, binding in full-site mode was almost completely 
abrogated for the PPARγ:RXRα-DBDmut (38/39 full-sites were lost). Of these sites, 40% 
(15/38) were now bound in the 5’ half-site mode (e.g., Fig. 2.3f , curation of modes can 
also be found in Supplementary Data 5 of (Penvose et al., 2019), demonstrating an 
altered binding mode for the PPARγ:RXRα-DBDmut heterodimer. The remaining 60% 
(23/38) of these sites were bound with low affinity by PPARγ:RXRα-DBDmut, and 
scored below our z-score threshold for modeling interactions. The reciprocal mutant 
experiment with PPARγ-DBDmut:RXRα showed a complete loss of binding (i.e., z-
score < 3.0) to nearly all of the full-sites (35/36, note that we have disregarded three 
sequences in this category as described above, model curations can also be found in 
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Supplementary Data 5 of (Penvose et al., 2019). These results demonstrate that DNA 
must be engaged by both dimer partners in order for PPARγ:RXRα to utilize a full-site 
binding mode, and shows that half-site binding can occur when only one partner can bind 
DNA. 
Next, I examined which partner of the wild-type PPARγ:RXRα dimer engages 
with DNA when binding in a half-site mode. Of the 34 sequences that PPARγ:RXRα 
bound in a half-site mode, 53% (18/34) remained bound in half-site mode by 
PPARγ:RXRα-DBDmut, demonstrating that for these sequences PPARγ is making base-
specific contacts with the DNA and can tolerate loss of base-specific DNA contacts 
mediated by RXRα (Fig. 2.3f). For the remaining 47% (16/34) of sequences bound by 
PPARγ:RXRα in a half-site mode, the mutant dimer binding was too low affinity to 
model (i.e., z-score < 3.0). Interestingly, PPARγ-DBDmut:RXRα showed a loss of 
binding to 82% (29/32, note two sequences in this category were disregarded due to 
residual PPARγ-DBDmut binding as detailed above) of the half-site sequences. These 
results demonstrate that a single partner of an NR heterodimer can mediate half-site 
binding; however, for other sites, mutation of either NR partner can lead to loss of 
heterodimer binding. The strong impact of mutations to either member of the heterodimer 
may be attributable to the ability of either partner to engage with the half-site, or to a 
contribution in binding energy through non-specific interactions from the non-engaged 
partner, which were abrogated by the mutations we made. 
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2.3.5 NR spacer preferences do not define high-affinity binding 
Previous studies have examined the impact of DR spacer length on NR binding 
(Cotnoir-White et al., 2011; Evans and Mangelsdorf, 2014; Kurokawa et al., 1993; 
Perlmann et al., 1993); however, my results demonstrate that NRs can bind in a half-site 
mode even on DR sites, which complicates the interpretation of these experiments as 
much of the binding examined may have been occurring to a single half-site and not to 
the full DR sequence. SNV binding models are advantageous as they allow examination 
of NR-binding mode on each sequence, thus facilitating a more rigorous assessment of 
NR spacer preferences. I analyzed the NR-binding landscape to all 24 seed sequences at 
each DR spacing and used the resulting binding logos to annotate whether each sequence 
was bound in a full-site or half-site mode (Fig. 2.4). 
In contrast to the prevailing view of NR spacer preferences (Cotnoir-White et al., 
2011; Evans and Mangelsdorf, 2014; Näär et al., 1991; Rastinejad et al., 1995), I found 
that NRs can bind with high affinity to DRs at all spacer lengths (Fig. 2.4). For most 
NRs, high-affinity binding to many DR spacer lengths is predominantly mediated via a 
half-site binding mode (Fig. 2.4 gray dots). Despite this promiscuous NR binding, my 
results recapitulate literature-reported NR spacer preferences, which are demonstrated by 
an enrichment of full-site binding mode and higher z-scores for specific DR spacer 
lengths (Fig. 2.4 blue dots). For example, PPARγ engages with DR1 sequences almost 
entirely via a full-site binding mode. Similar observations corroborate previously 
described DR-spacing preferences, for example LXRs (DR1 & DR4), THRα (DR4), and 
VDR (DR3) (see Fig. 2.1b). However, for most NRs the increase in binding affinity to 
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certain DR spacers is more modest than observed for PPARγ, suggesting that spacer 
preferences do not define the DNA binding landscape of each NR. In fact, for some NRs 
the canonical DR-spacing preferences appear primarily as enrichment in full-site binding 
mode, but not a large increase in binding affinity. For example, PPARα preferentially 
engages with DR1 sites in a full-site binding mode but only binds with moderately higher 
z-scores to these sites. My results reveal a complicated NR-DNA binding landscape in 
which DR spacer preferences contribute to altered NR-binding modes and binding 
affinity, but spacer preferences do not strongly define the landscape of all possible high-
affinity binding. 
2.3.6 Diverse mechanisms contribute to NR-DNA binding 
Despite broad similarities seen in binding logos (Fig.2.2), our dataset reveals that 
NR-binding differences result from multiple mechanisms: DR-spacing preferences, 
DNA-base preferences, and DNA-binding-mode differences. To illustrate the roles of 
spacing preferences and binding modes, we compared the binding of PPARγ and LXRα 
to DR1 and DR4 sites and observed both NR-shared and NR-specific binding sites (Fig. 
2.5a). The LXRα preference for DR4 sites and PPARγ preference for DR1 sites are 
demonstrated as biases in the z-score distributions. However, as we see high-affinity 
binding of PPARγ to DR4 sites and LXRα to DR1 sites, the aforementioned preferences 
do not explain all high-affinity binding. To explicitly test the impact of DR spacing, we 
examined binding to pairs of seed sequences that differ only in their spacer length (e.g., 
Fig. 2.5a, sequences DR1.1 and DR4.1). Critically, we examined the DNA-binding mode 
for each interaction using the DNA-binding logos generated for each seed sequence (Fig. 
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2.5b). For PPARγ, DR4 sites are bound with lower affinity than corresponding DR1 
variants (; however, DR4.1 is still bound with high affinity via a half-site binding mode 
(Fig. 2.5a,b). In contrast, when LXRα binds via a full-site mode the DR4 variant is bound 
with higher affinity (DR1.1 vs DR4.1), but when binding via a half-site mode the DR4 
variant is bound with lower affinity (DR1.2 vs DR4.2) (Fig. 2.5a). Therefore, both NRs 
can bind the same sequence with high affinity, but may utilize distinct binding modes. 
Taken together, these results demonstrate that both spacer preference and binding mode 
contribute to binding specificity. 
To investigate the plasticity of DR spacer preferences, we compared PXR and 
VDR, which exhibit broadly similar binding to DR1 and DR4 sites but differ for DR3 
binding. PXR and VDR bind with nearly identical specificity to DR1 and DR4 sites (Fig. 
2.5c, R2 = 0.98 for both); however, the VDR preference for DR3 sites is seen as an 
increase in z-score for most DR3 sequences (Fig. 2.5d). This example illustrates that NRs 
can bind similarly on one DR spacing while having distinct binding preferences for 
another DR spacing. 
Next, we asked whether shared spacer preferences might constrain DNA-base 
preferences. PXR and LXRα both exhibit preferences for DR1 and DR4 sites (Fig. 2.4); 
their binding profiles are highly correlated for DR1 sites (R2 = 0.95), but show lower 
correlation on DR4 sites (R2 = 0.83) (Fig. 2.5e). Analysis of the standard DNA-binding 
logos did not reveal a strong basis for differential DNA-base preferences. However, by 
directly examining the impact of SNVs on binding via visualization as an energy matrix 
(which indicates both favorable and unfavorable interactions), we see strong differences 
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between PXR and LXRα at positions 10 and 12 (Fig. 2.5f). The majority of the PXR-
specific binding sites are explained by the existence of a guanine base at position 10 that 
is highly disfavored by LXRα (G10 carries a z-score penalty of −3.21 for LXRα 
compared to −0.47 for PXR). We note that the highly unfavorable G10 preference for 
DR4 sites (Δz-score = −3.21) is not observed for DR1 sites (Δz-score = −0.65), 
demonstrating that this NR-specific preference is not shared across all spacer lengths 
(Supplementary Fig. 2.6). These results highlight the advantages of visualization of 
energy logos over traditional DNA binding logos, and demonstrate that novel base 
preferences can arise on DR sites of different lengths. 
In NR-binding logos, we observe base preferences in the spacer sequence between 
DR half-sites (e.g., Figs. 2.2, 2.5f, positions 12–15). We note a strong preference for an 
adenine in the spacer sequence of DR1 sites, which has been demonstrated for PPAR and 
other NRs (Bolotin et al., 2009); however, such a distinct base preference is absent at 
longer spacer lengths (DR2–DR5). To investigate the contribution of the spacer sequence 
to NR specificity, we examined how spacer variants modulate NR-DNA binding (Fig. 
2.5g). We focused our analyses on NRs that exhibit preferences for DR3 and DR4 sites. 
Examining the binding affinity distribution for SNVs within the spacer of a single seed 
sequence, we find that the spacer sequence can have considerable impact on binding 
affinity in an NR-specific manner (Fig. 2.5g), consistent with reports that NRs make 
DNA contacts with the spacer sequence (Lou et al., 2014). For instance, LXRa and 
LXRb shows a drop in affinity (D z-score ~-2) for the DR4 spacer sequence 5’-GAGG-
3’, while this spacer sequence does strongly impact the affinity for THRa, VDR, or PXR 
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(Fig. 2.5g, top panel, red line). Given the established role for DNA shape in TF binding 
specificity (Yang et al., 2014; Zhou et al., 2015), we investigated whether DNA shape 
features in the spacer sequence might also contribute to the selectivity for different 
binding sites. We examined DNA shape features for spacer variants of DR3 and DR4 
sites that enhance or diminish the binding of LXRα and VDR (Supplementary Fig. 2.7). 
The DNA shape features (i.e., major groove width, helix twist, propeller twist, and roll) 
examined are nearly identical for all comparisons. However, we observed a significant 
difference in the major groove width and roll parameters for VDR binding to DR3 sites. 
Our results suggest that DNA shape also plays a role in NR-binding specificity. Future 
studies that more exhaustively sample spacer sequences may enable identification of 
more subtle differences. 
2.3.7 Genomic binding agrees with in vitro binding preferences of LXRa and 
PPARg 
Our NR-binding landscape (Fig. 2.2) shows DNA binding to DR sites with many 
spacer lengths. To determine whether NRs use these diverse sites in vivo, we evaluated 
the ability of our PBM-derived models to explain in vivo-bound regions from published 
ChIP-seq datasets (Methods). Examining published PPARγ binding data in HT29 
colorectal cancer cells (GSE77039) (Savic et al., 2016), we find that all PPARγ models 
(DRs and half-sites) can discriminate bound regions from unbound. However, the DR1 
model best describes the data (area under the curve (AUC) = 0.70, Fig. 2.6a), in 
agreement with established PPARγ binding preferences and our PBM data (Fig. 2.4). 
Testing other published DR1 models (Methods and Supplementary Data 3 from (Penvose 
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et al., 2019) (Isakova et al., 2017; Kulakovskiy et al., 2013; Matys et al., 2006), we find 
the HOCOMOCO-f1 DR1 model performs best (AUC = 0.67) and with similar accuracy 
to our DR1 model. These results suggest that binding to DR1 sites is an important 
determinant of in vivo PPARg binding. In contrast, all models for LXRa yield similar 
AUCs (Fig. 2.6b), with the canonically preferred DR4 model performing similarly to the 
half-site models. Testing other published DR4 models we find JASPAR MA0494.1 
(DR4) performs the best (AUC = 0.63), and performs similarly to PBM-derived half-site 
models (AUCs = 0.64). These in vivo binding results are consistent with our in vitro 
binding data, which show a strong DR1 preference for PPARg and broader binding 
preferences for LXRa. 
2.3.8 Functional sites agree with canonical spacer preferences for LXRa and PPARg 
We hypothesized that functional binding sites that regulate gene expression may 
have a different motif composition than the full set of genomic binding sites. Binding 
sites were annotated as ‘functional’ if they were located within 10 kb upstream of the 
transcription start site of genes whose expression changed >2-fold upon agonist treatment 
(GSE77039 (Savic et al., 2016), Methods). We then performed motif enrichment analysis 
for these functional PPARγ or LXRα binding sites. Strikingly, we observe an increase in 
the enrichment of the PPARγ DR1 and the LXRα DR4 models for their respective 
functional sites (Fig. 2.6c,d). These same trends are observed when we use alternate 
genomic constraints to define functional sites (i.e., 10 kb up- and downstream, or 50 kb 
upstream) (Supplementary Fig. 2.8). These results are consistent with a model wherein 
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NRs preferentially utilize DR full-sites at a canonical spacing for activating transcription, 
while genome-wide binding is determined by a broader set of DR and half-site sequences, 
consistent with our in vitro binding data. 
2.3.9 LXRa binding via a half-site mode can drive gene expression 
Our analyses reveal widespread binding of NRs to half-site sequences both in 
vitro and in vivo. Furthermore, I showed that half-site mode is utilized by NRs to bind 
not only to half-sites, but also to canonical DR sites. To determine whether NR half-site 
mode binding is functional and can drive gene expression, I assayed the ability of LXRα 
to activate a reporter gene from a binding site bound in a half-site mode on our PBM. 
Expression of luciferase reporter genes was monitored in HEK293T cells in the presence 
of over-expressed LXRα:RXRα and ligand or vehicle (Materials and Methods). I found 
that LXRα strongly induces gene expression, in a ligand-dependent manner, from a DR1 
site (DR1.7) that is bound in a half-site mode by PBM (Fig. 2.7a, b, logo illustrates the 
5’-half-site binding mode). Ablating the 5’ half-site sequence (DR1.18) abrogates binding 
and drastically reduced reporter gene expression (from 36-fold induction down to 4-fold 
induction). Ablating the 3’ half-site (DR1.17) does not affect binding affinity; however, 
unexpectedly, it strongly decreased reporter gene expression (from 36-fold induction 
down to 9-fold induction), demonstrating that in vitro affinity does not necessarily predict 
binding-site activity. Therefore, NRs binding via a half-site mode in vitro can drive gene 
expression, but DNA bases that do not affect binding affinity in vitro can affect function 
in vivo. 
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2.3.10 LXRa and PPARg spacing preferences are defined by function not affinity 
I next examined the ability of LXRα and PPARγ to promote gene expression from 
a range of DR1 and DR4 binding sites (Fig. 2.7c). In general, PPARγ drives higher levels 
of gene expression from DR1 sites, and LXRα functions better on DR4 sites, in 
agreement with their canonical spacer preferences. However, I see exceptions to these 
simple rules. First, LXRα can promote expression from the DR1.7 site (Fig. 2.7a) at a 
comparable or higher level than from the three DR4 sites (Fig. 2.7c). Second, for PPARγ, 
several high-affinity DR1 sites (DR1.8, DR1.3) show comparable or lower activity than 
the three DR4 sites, which are all bound with comparable or lower affinity. Complicating 
the interpretation, without NR overexpression, the DR4 sites exhibit lower reporter gene 
activity than DR1 sites (Supplementary Fig. 2.9). This low basal activity may exaggerate 
the NR-dependent activation determined for these sites, which is calculated as the fold-
change between basal and NR-over-expressed conditions. Despite these complications, it 
is clear that affinity does not strongly predict activity of different NRs. 
2.4 Discussion 
Here we report the most comprehensive DNA binding dataset to date for the type 
II NRs, and provide a revised framework for interpreting NR-binding and regulatory 
specificity. I demonstrate more promiscuous DNA binding for NRs than has been 
previously reported, challenging the view that NR-binding specificity is defined solely by 
distinct DR spacer preferences. These findings agree with other PBM-based studies of 
NR homodimers that demonstrated nearly identical binding for RXRα and COUP-TF2, 
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and found that NR specificity does not solely depend on DR-spacing rules. We 
demonstrate that NR-binding-site activity does not follow binding affinity, and that the 
canonical NR DR spacer-length preferences better reflect activity rather than DNA-
binding-site affinity. Our revised framework for NR-binding and function shows that 
NRs bind DNA via two binding modes to a broad set of DR and half-site sequences; this 
binding corresponds with in vivo binding, but does not correspond to in vivo function, 
which may involve additional layers of specificity (e.g., allostery) (Fig. 2.7d). Future 
studies that focus on refining the rules for NR-binding-site activity will clarify this 
general framework and improve genomic analyses aimed at predicting NR-dependent 
gene regulation, or the impact of SNPs on NR function, as in a recent analysis of PPARγ 
function. 
Our study challenges the prevailing view that each NR heterodimer prefers 
binding to DR sites of specific spacer lengths. We show that all NRs can bind with high 
affinity to many DR spacer lengths in a full-site binding mode. Previous studies that 
sought to identify DR spacer preferences did not explicitly account for multiple NR-
binding modes, potentially complicating their interpretations (Cotnoir-White et al., 2011; 
Evans and Mangelsdorf, 2014; Kurokawa et al., 1993; Perlmann et al., 1993). While we 
observe previously described DR spacer preferences, our study suggests a distinct 
biophysical interpretation for these preferences. We propose that DR preferences of NRs 
are not based on a large increase in binding affinity, but arise from a preference to bind in 
a full-site mode over a half-site mode, coupled with a moderate increase in affinity (i.e., 
LXRα and PPARα, Fig. 2.4). The implication that NR spacer preferences are primarily 
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about binding mode, rather than affinity, may provide a biophysical interpretation of NR 
preferences that links binding mode to in vivo function. 
The disagreement between the promiscuous NR binding seen in our study and the 
canonical DR spacer preferences reported in the literature may be explained by 
differences in the approaches utilized. DR spacer preferences were initially characterized 
on a small number of DNA sequences obtained from promoter regions of genes that were 
upregulated upon ligand treatment, naturally biasing towards functional genomic binding 
sites (Cotnoir-White et al., 2011; Evans and Mangelsdorf, 2014; Kurokawa et al., 1993; 
Mader et al., 1993). Other high-throughput methodologies used to examine NR 
heterodimer binding preferences bias towards high-affinity binding sites and thus do not 
capture the full landscape of NR-binding specificity (Isakova et al., 2017). Our PBM 
approach, which queried the binding across a broad range of affinities and DR spacer 
lengths, reveals a more promiscuous NR-binding landscape. 
Our NR-binding data are consistent with in vivo binding, and provide an updated 
framework for interpreting genome-wide binding data. For example, PPARγ ChIP-seq 
peaks are best modeled by a DR1 motif, consistent with the high-affinity binding 
observed for DR1 sites. In contrast, LXRα ChIP-seq peaks are modeled equally well by 
most DR models and half-sites (Fig. 2.6), consistent with broader in vitro specificity for 
LXRα. We note that a DR4 motif was identified by de novo motif analysis using this 
LXRα ChIP-seq dataset (Savic et al., 2016), but only when restricting the analysis to the 
highest scoring ChIP-seq peaks; when motif finding is performed on the full dataset, a 
half-site motif is identified. This example illustrates a source of confusion in the field: 
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reinforcement of established NR-binding preferences by conclusions supported by only a 
small fraction of the genome-wide binding data (Boergesen et al., 2012; Everett and 
Lazar, 2013; Savic et al., 2016). Re-interpreting the genomic data in light of our dataset, 
we find that the broader specificity found in vitro is consistent with in vivo binding. 
Unexpectedly, we found that all type II NR heterodimers have the ability to bind 
DNA via a half-site mode on both full-sites and half-sites. This is a clear example of 
DNA-based allostery, in which interactions with DNA alter the structure of DNA-bound 
TFs. Allostery has been reported for the NRs (Gronemeyer and Bourguet, 2009; Meijsing 
et al., 2009; Schöne et al., 2016; Watson et al., 2013), and provides a mechanism to 
decouple affinity and activity. A provocative idea is that NR-binding mode can predict 
activity and explain NR functional preferences. Supporting this idea, a recent study of the 
glucocorticoid receptor (GR), a steroid hormone nuclear receptor, showed that GR 
homodimers can bind to half-site sequences in vivo to repress gene expression (Hudson 
et al., 2012). Our data on the preference of PPARγ and LXRα to bind in a full-site mode 
and drive gene expression from DR1 and DR4 sites, respectively, offer additional support 
for this idea. Other work has demonstrated that NR binding can be altered by coregulator 
proteins (Issa et al., 2001; Lefebvre et al., 1998), raising the possibility that NR binding 
modes may be altered in the presence of endogenous coregulators. Future studies that 
assess NR-DNA binding and binding modes in the presence of coregulators will help 
clarify the relationship between NR-binding mode, affinity, and activity. Our PBM 
dataset provides a valuable resource for these future studies aimed at elucidating the 
mechanisms of NR specificity in gene regulation. 
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2.5 Materials and Methods 
2.5.1	Protein expression and purification 
For all of the NRs used within this study, I cloned the human coding regions for 
the proteins into both N-terminal His-tag and GST-tag expression vectors for E.coli 
expression (pDEST 15 and pDEST17 vectors, respectively) and mammalian expression 
(pDEST26 and pDEST27, respectively). Over the course of three years, I made many 
attempts to purify all of the NRs myself, from both E. coli and from the human HEK 293 
Freestyle cell line. I tested many different E. coli expression strains (BL21(DE3), 
C41(DE3), BL21(pRARE), and Arctic Express), tags (His, GST, FLAG) and expression 
conditions (temperature, density at induction, strength of induction). However, after three 
years I had only obtained full-length protein that showed sequence-specific DNA binding 
by EMSA for PPARg and RXRa, and the decision was made to purchase the remaining 
NRs. Expression of full-length NRs in E. coli is known to be difficult as most of the 
protein ends up in inclusion bodies (Mossakowska, 1998). Expression in mammalian 
cells led to lower yield and purity, and we chose not to continue to pursue this method of 
expression. Throughout the expression and purification process, the yield and purity of 
the protein were checked by SDS-PAGE and western blotting (Supplementary Fig. 2.10 
a-d). For samples for which the yield and purity was high, the activity of the protein (e.g, 
ability to bind DNA in a sequence-specific fashion) was tested using EMSA 
(Supplementary Fig. 2.11). For purchased proteins, the proteins were checked by western 
blot using an antibody against the epitope-tag (Supplementary Fig. 2.12) and with NR-
specific antibodies before proceeding to PBM experiments. The type II NRs not included 
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in this study were left out because I was unable to purify or purchase full-length, active 
protein.  
Full-length, wild-type human RXRα and PPARγ isoform 1 constructs were cloned 
into the Gateway vector pDEST17 (LifeTech) for propagation, mutagenesis, and 
expression. A TEV-protease recognition sequence was included between the coding 
sequence of the His-tag and RXRα and used to cleave the His-tag after purification. His-
tagged RXRα and PPARγ were expressed using the BL21(DE3) E. coli strain (NEB). 
Transformed bacteria were propagated on Luria-Bertani broth (LB) plates supplemented 
with 100 µg/ml of carbenicillin. Protein expression was carried out in LB supplemented 
with 100 µg/ml of carbenicillin, with an initial outgrowth at 37 °C up to an OD of 0.4, 
transferred to ∼20 °C until they reached an OD of 0.6–0.7 and then induced with 1 mM 
IPTG. Protein was expressed at room temperature (∼20 °C) for 3 h. Cells were pelleted 
and stored at −80 °C until purification. Purification was carried out using HisTrapFF 
columns (GE Healthcare). The binding buffer was composed of 20 mM Tris HCl pH 7.4, 
300 mM NaCl, 25 mM Imidazole, and 1 mM dithiothreitol (DTT) and the elution buffer 
was composed of 20 mM Tris HCl pH 7.4, 300 mM NaCl, 250 mM Imidazole, and 1 mM 
DTT. Buffers were supplemented with cOmplete Mini protease inhibitor tablets 
according to the manufacturer’s instructions (Roche). Eluted fractions were analyzed by 
SDS-PAGE and fractions containing protein were combined. For PPARγ, the combined 
elution fractions were buffer exchanged into phosphate buffered saline pH 7.4 with 1 mM 
phenylmethylsulfonyl fluoride (PMSF) and 10% glycerol using an Amicon Ultra 
centrifugal filter (30k MWCO). Elution fractions of RXRα were dialyzed against three 
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changes of binding buffer. Next, the His-tag was cleaved from RXRα by overnight 
incubation at 4 °C with TEV protease (Sigma–Aldrich). After cleavage, the RXRα 
sample was re-purified as described above; however, this time the flow-through fraction 
from the column loading was collected and used in all PBM experiments, as this fraction 
contained the RXRα from which the His-tag was successfully cleaved. The combined 
flow-through fractions were buffer exchanged into phosphate buffered saline pH 7.4 with 
1 mM PMSF and 10% glycerol using an Amicon Ultra centrifugal filter (30k MWCO). 
The RXRα and PPARγ DNA binding domain mutants were made by site-directed 
mutagenesis using the NEB Q5 site-directed mutagenesis kit (New England Biolabs) 
following the manufacturer’s instructions.  
Primers used for the mutagenesis:  
RXRα-DBDmut:  
Forward = 5’-CTTCTTCTTCAAGGCGACGGTGCGCAAGGACCTG,  
Reverse = 5’- CCCGCGCACCCCTCGCAGCTGTACACTCCATCAGC;  
PPARγ-DBDmut:  
Forward = 5’-CTTCCGGGCAACAATCAGATTGAAGCTTATCTATGACAG, 
Reverse = 5’- AAACCCGCGCATCCTTCACAAGCATGAACTCCATAGTG.  
For DNA binding domain mutant experiments, PPARγ, RXRα, PPARγ-DBDmut, 
and RXRα-DBDmut were expressed using the PURExpress IVT kit (NEB) according to 
manufacturer instructions. The concentration of all IVT-produced proteins was estimated 
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by western blot by comparison to purified proteins (Supplementary Fig. 10 d&e). All 
other purified proteins used were purchased (see Table 2.1 for details). 
2.5.2 SDS-PAGE 
For SDS-PAGE quality control experiments (Supplementary Figs. 2.10), proteins 
were separated by electrophoresis on 10-well 4-20% Mini-Protean TGX gels (Bio-Rad). 
Proteins were denatured in Laemmli sample buffer (Bio-rad) at 95 °C for 10 min. For raw 
lysate and elution fractions (Supplementary Fig 2.10a and 2.10b) 15 µl of lysate with 5 µl 
of 4x Laemmli. For the concentrated and buffer exchanged samples 0.5 µl of PPARg was 
used (Supplementary Fig 2.10c) and 1 µg of RXRa was used (Supplementary Fig. 
2.10d), each in a final volume of 20 µl. Precision Plus All Blue Pre-stained Protein 
Standard (Bio-Rad) was also loaded onto the gels. Gels were electrophoresed until the 
bromophenol blue dye front reached the bottom of the gel.  
2.5.3 Western blotting 
Proteins were detected by western blotting using antibodies that recognized either 
the protein or the epitope-tag. For western blot experiments, proteins were separated by 
SDS-PAGE electrophoresis and then transferred to 0.2 µm nitrocellulose membrane 
(Millipore) for 1.2 hr at 100 V. The membrane was rinsed with deionized water and then 
incubated in blocking buffer (3% milk in PBS pH7.4 with 0.05% Tween-20) for 1hr at 
room temperature. Membrane was rinsed 3 x 5 min in PBST (PBS pH 7.4 with 0.05% 
Tween-20). Next, membranes were incubated with primary antibody diluted in PBST for 
2 hr at room temperature. Primary antibodies were used at a 1:2000 dilution and included 
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anti-RXRα (Active Motif 61029), anti-His (Sigma H1029), and anti-PPARγ (Abcam 
ab41928). After the 2 hr incubation in primary antibody, the membrane was rinsed 3 x 10 
min in PBST and then incubated for 1 hr at room temp in horseradish peroxidase-
conjugated goat anti-mouse antibody (Abcam ab205719) diluted at 1:5000 in PBST. 
Next, the membrane was rinsed 3 x 10 min in TBST. Membranes were developed in 
Supersignal west chemiluminescent substrate for 5 min (Thermo Scientific 34087). 
Chemiluminescence was detected on radiography film and developed on a Kodak M35 
X-OMAT Processor (Kodak Diagnostic Imaging).  
2.5.4 Radiolabeled Electrophoretic Mobility Shift Assay 
Double-stranded (ds) DNA oligonucleotides (60 bp) were prepared by primer 
extension (45 µL total) using 8 µM of 60-bp ssDNA template (IDT Technologies, 
sequences given below), 8 µM of 24-bp extension primer , 1.6 mM dNTPs (New England 
BioLabs), and 1x ThermoPol Reaction Buffer (NEB). A separate enzyme mixture (5 µL 
total) was prepared with 4 units of Bst DNA polymerase- Large fragment (NEB) and 1x 
ThermoPol Reaction Buffer. Reaction mixtures were heated in a thermocycler to 95˚C, 
and gradually cooled to 63˚C by decreasing the temperature by -0.1˚C/s. The enzyme mix 
was placed in the thermocycler for 1 min to equilibrate to temperature, and then 5 µL of 
this mix was pipetted into each 45 µL reaction mixture. The reactions were incubated at 
63˚C for an additional 90 min to allow completion of the primer extension reaction. The 
double-stranded DNA was purified from the extension reaction using a MinElute PCR 
Purification Kit (Qiagen) per the manufacturer’s instructions. DNA probes were 
radioactively labeled using T4 polynucleotide kinase (PNK) (NEB) and ATP [γ32P] 
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(Perkin Elmer). For each probe, 2 pmol of oligonucleotide was incubated with 10 units of 
T4 PNK and 20 µCi ATP [γ32P] in 1x PNK Buffer (15 µL total reaction) @ 37˚C for 2 
hr. After labeling, the probe was purified using a QIAquick Nucleotide Removal Kit 
(Qiagen) following the manufacturers guidelines to remove residual ATP [γ32P]. 
DNA Probes (5’à3’): 
Note: For direct repeat sites, each half-site is bolded and underlined. 
Extension primer: CCTTCATTCTACGCTGTCAATCGC 
DR1: 
GCCAAACTAGGTCAAAGGTCAGCCAACCAGCGATTGACAGCGTAGA
ATGAAGG 
 
DR4: 
GCCAAACTAGGTCACGAAAGGTCAAAGTCGAATGACGCGATTGACA
GCGTAGAATGAAGG 
 
Non-specific competitor:  
GATAAGCGCCATTCAGGGGTCCACAGTTCACGTAGTGCGATTGACAGC
GTAGAATGAAGG 
 
DNA-binding reactions contained 1 nM 32P-labeled DNA in 1x EMSA Binding 
Buffer (1x PBS pH 7.4, 0.02% Triton-X-100, 1 mM dithiothreitol (DTT), 0.2 mg/mL 
bovine serum albumin (BSA) (NEB), and 5% v/v glycerol (Sigma). Protein 
concentrations used in each DNA binding reaction are listed in the figure (Supplementary 
Fig. 2.11). The DNA-binding reactions were incubated at room temperature for 30 min. 
Samples were electrophoresed for 1.7 hr at 70V on non-denaturing polyacrylamide gels 
(6% of 29:1 acrylamide:bisacrylamide [Fisher], 0.5x Tris Buffered EDTA [pH 8.3]. Gels 
were dried under suction for 1.5 hr at 80˚C, using a BioRad Gel Dryer. Dried gels were 
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placed onto a PhosphorImager (GE Healthcare) and left to expose overnight (~12 hours). 
DNA bands were visualized using a Typhoon Trio scanner (GE Healthcare) with a 100 
µm pixel size.  
2.5.5 PBM custom design 
PBM experiments were performed using custom-designed microarrays (Agilent 
Technologies Inc. AMADID 084387, 4 × 180 K format). PBM probes contain a 24 nt 
constant primer region, a 34 nt variable region, and a 5’ GC dinucleotide cap (probe 
sequences can be found in Supplementary Data 4 of (Penvose et al., 2019)). For each 
unique SNV probe sequence, five replicate probes were included in each orientation (10 
probes per unique sequence). For all other probe sequences four replicate probes were 
included with the 34 nt variable region in each orientation (8 probes per unique 
sequence). 
Seed probes: Direct repeat seed probes were generated from a variety of flank and 
half-site combinations. The starting half-site sequences were chosen from the literature as 
variations from the 5’-AGGTCA-3’ consensus half-site (Literature curation of binding 
sites can be found in Table 2.2). Any given seed half-site varied from the consensus half-
site by at most 2 bases. For SNV modeling we require that the seed sequence z-score > 3 
and I chose not to vary the starting half-site more than 2 bases from the consensus half-
site as more variation than this would likely lead to a low scoring seed sequence that 
would not be able to be modeled.  
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For each seed sequence, I created a corresponding spacer set at spacer lengths of 
0-5 nt (DR0-5) (Seed-spacer sequence sets can be found in Table 2.6). For any given 
spacer set, the flanks and half-sites for that set are held constant and only the spacer 
length and sequence are varied. This allowed me to directly compare the affinity for 
different flank and direct repeat sequences at different spacer lengths. One limitation of 
this design is incomplete sampling of the spacer sequence at longer spacer lengths (DR3-
DR5). Care was taken to design spacer sequences with as much variety as was possible 
given the space limitations on the PBM. Spacer sequences were taken from binding sites 
reported in the literature (Table 2.2) and directly designed to introduce starting sequence 
diversity.  
SNV probes: DR seed sequences, defined by two 6-bp half-sites and a variable 
spacer (0–5 bp), were aligned within the 34 nucleotide variable region of each PBM 
probe. For each seed sequence, SNV probes were created that had a single-nucleotide 
variant at each position of the DR half-sites, the spacer sequence between the DR half-
sites, and in the 5 bp flanks of each site. Therefore, for a single 13 bp DR1 site (i.e., 
6 + 6 + 1 = 13), including 5 bp flanks on either side, there would be 69 (i.e., 23 × 3) 
unique SNV probe sequences.  
Half-site ablation probes: For each DR seed sequence, probe variants were 
created with each half-site ablated. Ablations were performed by identifying the position 
in the half-site that contributes most to the NR-binding score and replacing it with a 
penalizing base. Ablations probes were conceptually designed by Ashley Penvose and 
Jessica Keenan. Jessica Keenan did the scripting to create the probes. 
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Random genomic probes: 34 nt regions were randomly chosen from the UCSC 
hg19 build of human genome. Sequences were removed that contained Ns or single-
nucleotide repeats longer than three nucleotides. 
Other probes: This array design also included a variety of other probe types 
including DRs at longer spacer lengths (DR6-DR9), inverted repeats (IR0-9), and everted 
repeats (ER0-9). Due to space limitations on the 4x180k array, sites of these types were 
included as individual probes, rather than as full seed and SNV sets. The intention of this 
design was to gain insight into which alternative site arrangements show high affinity 
binding for each NR dimer and require further investigation in future studies. The 
exclusion of these probes from my analyses is discussed in section 2.6.1. 
2.5.6 PBM experiments and analysis 
See Table 2.1 for protein concentrations used for each NR. For all NR 
heterodimers, the RXR partner was initially tested at a concentration of 270nM. When 
experiments showed poor agreement between antibody replicates, which suggested we 
were measuring some non-heterodimeric binding, the concentration of the RXR partner 
was lowered. This was the case for PPARg and THRa. For the PBM experiments on 
individual NRs, each NR was used at the same concentration as in the heterodimer 
experiment. RXRα alone was tested at 180 nM, as this would yield a homodimeric 
receptor concentration of 90 nM, which is the same concentration that was tested for the 
heterodimers. 
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Microarrays were double-stranded as previously described (PBM double-
stranding primer 5’-CCTTCATTCTACGCTGTCAATCGC-3’) (Berger and Bulyk, 2009; 
Berger et al., 2006a). All washes were performed in coplin jars on an orbital shaker at 
125 rpm. Double-stranded microarrays were first pre-wetted in phosphate buffered saline 
(PBS) containing 0.01% Triton X-100 for 5 min, rinsed in a PBS bath, and then blocked 
with 2% milk in PBS for 1 h. After blocking, arrays were washed in PBS containing 0.1% 
Tween-20 for 5 min, then in PBS containing 0.01% Triton X-100 for 2 min and then 
rinsed in a PBS bath. Proteins were then incubated on the array for 1 h in a binding 
reaction containing: PBS pH 7.4 with 2% milk, 0.02% Triton X-100, 1 mM DTT, 
0.2 mg/ml bovine serum albumin, and 0.4 mg/ml salmon testes DNA (Sigma D7656). 
Preliminary PBM experiments for PPARγ:RXRα and RXRα were performed with and 
without the ligands rosiglitazone and 9-cis retinoic acid, respectively, and we found no 
change in NR binding; therefore, all experiments were performed in the absence of 
ligand. Following the protein incubation, microarrays were washed with PBS containing 
0.5% Tween-20 for 3 min, then in PBS containing 0.01% Triton X-100 for 2 min 
followed by a brief PBS rinse. Microarrays were then incubated with 20 µg/ml of primary 
antibody in 180 µL of 2% milk in PBS for 20 min. For heterodimers, separate 
experiments were performed using an antibody against each protein within the 
heterodimer. In all experiments, anti-RXRα antibody (Active Motif 61029) was used to 
detect RXRα and anti-His antibody (Sigma H1029) was used to detect the NR partner 
with the following exceptions: anti-PPARγ antibody (Abcam 41928) was used in all 
experiments with PPARγ, and Alexa488-conjugated anti-GST antibody (Life Tech 
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A11131) was used for all PPARα experiments. Excess primary antibody was removed by 
washing with PBS containing 0.05% Tween-20 for 3 min and then in PBS containing 
0.01% Triton X-100 for 2 min. Arrays were next incubated with 20 µg/ml of Alexa488-
conjugated secondary antibody (anti-mouse A488, Life Tech A11001) in 180 µL of 2% 
milk in PBS for 20 min (PPARα was probed with an Alexa488-conjugated anti-GST 
primary antibody as described above and did not require a secondary antibody). Excess 
antibody was removed by washing 2x with PBS containing 0.05% Tween-20 for 3 min 
and then in PBS for 2 min. Microarrays were scanned with a GenePix 4400 A scanner 
and fluorescence was quantified using GenePix Pro 7.2. Exported data were normalized 
using MicroArray LINEar Regression (Berger et al., 2006a). Microarray probe sequences 
and fluorescence values from each experiment are provided (See Supplementary Data 4 
of (Penvose et al., 2019)). NR dimers exhibit an orientation-specific bias in our PBM 
experiments; therefore, data from probes in a single orientation (i.e., ‘_o1′ probes in 
Supplementary Data 4 of (Penvose et al., 2019)) was used in our final analysis. However, 
all results were observed for probes in both orientations and models from each orientation 
showed good agreement. 
Position frequency matrices (PFMs) and DNA-binding logos were generated for 
each seed sequence with z-score >3.0 using the previously described SNV-based 
approach (Andrilenas et al., 2018), with β set to 15/maximum z-score. Briefly, logos for 
single seed sequences are generated using the binding data to each seed sequence and all 
the single-nucleotide variant (SNV) sequences for that seed sequence. For a binding site 
of length L there will be 3xL SNV sequences. Logos for an NR binding to a specific DR 
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spacer length are determined by averaging over the individual seed sequence logos. To 
generate logos for a specific DR spacer length (Fig. 2.2), PFMs for all seed sequences at 
that spacer length were clustered into full-site, 5’-half-site or 3’-half-site PFMs. Average 
PFMs of each type (i.e., full, 5’-half-site or 3’-half-site) were then generated by directly 
averaging over the individual PFMs (i.e., averaging individual matrix elements and 
normalizing each column to 1). As the half-site PFMs are the same length regardless of 
the starting DR seed length, the final 5’-half-site and 3’-half-site PFMs were further 
averaged over PFMs generated at all spacer lengths. The z-score energy matrix (Fig. 2.5f) 
was generated in the same manner, without the initial transformation from z-score to 
frequency (Andrilenas et al., 2018). 
2.5.7 Reporter gene assays 
PPARγ, LXRα, and RXRα were cloned into the N-terminal His-tagged protein 
mammalian expression plasmid pDEST26 (LifeTech). Reporter constructs for test 
sequences were ordered synthesized (Twist Bioscience) and were flanked by two BsaI cut 
sites, which were used to clone the sequences into pNL3.1-minP/Nluc (Promega). All 
sequences tested can be found in Table 2.5. HEK293T (ATCC) cells were cultured in 
DMEM (Gibco 11965-092) supplemented with 10% FBS (Gibco 26140079). Cells were 
plated in tissue culture treated 96-well plates seeded at a density of 12,500 cells per well 
and allowed to adhere overnight. PEI:DNA complexation reactions were prepared at a 
ratio of 3:1 (PEI:DNA) in 500 µl of Opti-MEM (Gibco 51985-034) and allowed to 
complex for 20 min at room temperature. Each 96-well plate well received 20 µl of 
transfection mixture containing 16 ng of total plasmid: 1 ng of transfection normalization 
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plasmid (pGL4.54-Luc2/TK); 10 ng of reporter plasmid (pNL3.1-minP/Nluc); and either 
5 ng of empty pDEST26 for the no overexpression conditions (NoOE); or 2.5 ng of 
RXRα in pDEST26 combined with either 2.5 ng of PPARγ or LXRα in pDEST26 for 
protein overexpression condition (OE). Twenty-four hours after transfection, 80 µl of 
media was removed from each well and replaced with 80 µl of fresh media containing the 
appropriate ligand treatment. PPARγ ligands were 1 µM rosiglitazone (Sigma–Aldrich) 
and 1 µM T0070907 (Sigma–Aldrich). LXRα ligands used were 1 µM GSK2033 (Sigma–
Aldrich) and 500 nM T0901317 (Sigma–Aldrich). Luciferase activity was assessed 18 h 
after addition of the ligand using the Nano-Glo Dual Luciferase reporter assay system 
(Promega). Dual luciferase signal was quantified using a VICTOR-3 plate reader 
(PerkinElmer). To control for transfection efficiency, the Nanoluc (Nluc) reporter 
plasmid signal was normalized to the constitutive luciferase signal (Luc2) (i.e., signal 
from pGL4.54 plasmid) (Nluc/Luc2). Normalized signal for all test DNA elements were 
then further normalized to empty vector (pNL3.1-Nluc with an insert of equal length to 
test sequences but lacking any half-site or direct repeat sequences). Fold-induction values 
for each protein + reporter combination were calculated relative to the background 
activity of each reporter plasmid in the absence of protein overexpression: 
(protein + reporter)/(control + reporter) = OE/NoOE (Supplementary Fig. 2.9). Reporter 
assays were performed as three biological replicates with three technical replicates per 
biological replicate. 
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2.5.8 Competition Electrophoretic Mobility Shift Assay (EMSA) experiments 
Complementary DNA oligonucleotides (from Integrated DNA Technologies, 
sequences in Table 2.4) were annealed in a thermocycler by raising the temperature to 
98 °C and reducing the temperature by 0.1 °C/sec until a temperature of 4 °C was 
reached. EMSA buffer formulation for all reactions was 1x PBS pH 7.4 with 0.2% BSA, 
5 mM DTT, 10% glycerol, and 0.02% Triton-X100. For the direct binding experiment, 
1 nM of IR700-labeled P1 probe (Integrated DNA Technologies) was incubated with 
varying concentrations of PPARγ:RXRα in a 20 µL reaction. For competition 
experiments, 2 nM of IR700-labeled P1 probe was incubated with PPARγ:RXRα 
(12 nM:4 nM) in a 20 µL reaction with various concentrations of unlabeled competitor 
sequences (0, 0.2, 0.63, 2, 6.3, 20, 63, 200, 630, and 2000 nM). Reactions were incubated 
for 1 h at room temperature and then electrophoresed in 0.5x Tris Boric Acid EDTA 
Buffer (TBE ) on a 6% TBE-acrylamide gel at 50 V for 3 h. Gels were scanned on the 
Odyssey CL-X (LI-COR) at 84 µm resolution. Fluorescence of the shifted band was 
quantified using ImageStudioLite software. All Kd calculations were done with DynaFit 4 
software (Kuzmič, 1996) using a previously described competition protocol (Golden et 
al., 2013). Percent competition was calculated by the formula: 
% inhibition = (F0- Fc)/F0*100 
F0: fluorescence of shifted band with no competitor DNA 
Fc: fluorescence of shifted band at given concentration of competitor DNA. 
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2.5.9 Enrichment of NR-binding sites in ChIP-seq data 
Receiver-operating characteristic (ROC) curve analyses were performed to quantify the 
extent to which NR-bound (true positive) regions scored more highly than unbound (true 
negative) regions with PWM models. True-positive regions for LXRα and PPARγ were 
derived from ChIP-seq data from HT29 colorectal cancer cells (GSE77039) (Savic et al., 
2016). ChIP-seq was available for two biological replicates of HT29 cells treated with 
agonist (GW3965 for LXRα or rosiglitazone for PPARγ) for 2 h and 48 h. For each NR, 
ChIP peaks with 50% reciprocal overlap within time points and between time points were 
considered true-positive regions. True-negative regions were derived from DNase-seq of 
HT29 cells (GSE90403) (Consortium, 2012). Regions with 50% reciprocal overlap 
between the two available DNase-seq biological replicates were identified, and all ChIP 
peaks from the corresponding NR ChIP datasets were then subtracted from the DNase-
seq regions. Regions matched in size to each ChIP-derived true-positive region were 
randomly chosen from ChIP-subtracted DNase-seq regions to create the true negative 
regions. Background nucleotide frequencies for calculating PWMs from PFMs were 
taken from the nucleotide distribution of the DNase-seq regions with 50% reciprocal 
overlap between the two replicates. To score sequences, the following formalism was 
used: 
𝑝#,%&	(),*	+	,-)∑ (),*	+	,)  
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Probability of an A,C,G or T (i = 0,1,2,3 respectively) occurring at position j of the 
sequence being evaluated. 
fi,j: frequency defining the position frequency matrix 
bi: nucleotide background frequencies: A: 0.24; T: 0.24; C: 0.26; G: 0.26 
s: pseudo-count to deal with zeros (s = 0.001) 
The PWM score is the sum over all base positions (j) of the corresponding Si,j values for a 
particular sequence: 
𝑠#,% = 	 𝑙𝑜𝑔4(𝑝#,%𝑏# ) 
 
Area under the ROC curve (AUC) values are reported to quantify the enrichment, 
and a Wilcox-Mann-Whitney (WMW) U test was applied to calculate the significance of 
each AUC value. AUC and WMW U test values were calculated in the R statistical 
package using the wilcox.test function. All manipulations of genomic regions 
(identification of overlapping regions, region subtractions, etc.) were performed with 
BEDTools 2.26.0 (Quinlan and Hall, 2010). 
To examine the motif enrichment of currently available models, we performed the 
ROC analyses described above with publicly available PFMs. Each PFM was normalized 
such that the nucleotide frequencies at each position sum to 1. The following models 
were used: LXRα (MA0494.1(Khan et al.); HOCOMOCO f1 (Kulakovskiy et al., 2013)), 
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PPARγ (Isakova et al., 2017); M00512, M00515, M00528 (Matys et al., 2006); 
MA0065.1, MA0065.2, MA0066.1 (Khan et al.); HOCOMOCO f1, HOCOMOCO s1 
(Kulakovskiy et al., 2013)). 
To examine motif enrichment for putative ‘active’ sites near differentially 
expressed genes, RNA-seq data from HT29 cells (Savic et al., 2016) were used to 
identify regions that are likely to be actively controlling transcription. We re-analyzed the 
published RNA-seq data using DESeq2 (Love et al., 2014) to identify genes upregulated 
upon agonist treatment compared to vehicle only (DMSO). Transcripts with a fold-
change greater than 2 and adjusted p-values less than 0.01 were considered upregulated. 
For PPARγ, transcripts upregulated after both 24 and 48 h of rosiglitazone treatment were 
considered for further analysis. For LXRα, transcripts upregulated after 48 h of GW3965 
and T0901317 treatment were considered for further analysis. For each NR, ChIP regions 
with 50% reciprocal overlap between replicates and time points and within the indicated 
regions associated with upregulated genes were considered active true positives for 
enrichment analysis. Regions matched in size to each active region were randomly 
chosen from the true-negative regions described above to create the true negative regions. 
ROC analyses were performed as described above. 
2.5.10 DNA shape analysis 
Binding to spacer-sequence variants of five DR3 and five DR4 seed sequences 
was analyzed (Supplementary Fig. 2.7). For each DR3 seed sequence, the PBM z-scores 
of the seed sequence and corresponding 9 SNV sequences (i.e., sequences with base 
variants at positions B1, B2, or B3) were analyzed to identify the two highest affinity and 
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the two lowest affinity sites for each of the five seeds, resulting in a total of ten high and 
ten low-affinity spacer variants. The same procedure was performed for the DR4 
sequences and the corresponding 12 SNVs at positions B1, B2, B3, and B4. For each of 
the 10 spacer variants, the following DNA shape parameters were calculated at each base 
position using the TFBSshape server (Yang et al., 2014): major groove width (MWG), 
helix twist (HelT), propeller twist (ProT), and roll. The distribution of the DNA shape 
parameters associated with high and low-affinity sequences were compared at each base 
position using a two-tailed t-test. 
2.6 Rationale and Limitations 
2.6.1 Rationale and limitations of our custom NR PBM design 
The PBM approach for measuring the DNA binding affinity of TFs has many 
advantages including the ability to capture TF-DNA interactions over broad range of 
affinities (Andrilenas et al., 2015). Our custom-designed NR PBM allowed us to directly 
compare the binding of the NRs to the same set of sequences without introducing the 
amplification biases that are common with many other high-throughput methodologies to 
measure protein-DNA interactions (Andrilenas et al., 2015). 
However, as is true with any technique, there are also a variety of limitations 
presented by the PBM methodology. As PBMs have a limited number of probes (~180k 
for a 4-chambered array), the first challenge in creating a custom-designed PBM is 
deciding what types of sequences to include on the array. We ultimately chose to use a 
seed and SNV design as this would allow us to generate models for individual sequences. 
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This SNV approach to modeling yielded the unique insight into the ability of NRs to 
utilize multiple binding modes to engage with DNA. However, as each seed and SNV set 
takes up a significant amount of space on the array (length of probe to be included in 
SNVs x 3 base variants in each position + 1 probe for starting seed), I was constrained in 
the number of seeds I could include at each spacer length. For longer spacer lengths 
(DR3-5), this space limitation on the PBM meant that I could not exhaustively test all 
possible sequences in the spacer. The sequence of the spacer is known to impact the DNA 
binding affinity of NRs, as NRs make sequence-specific contacts with this region of 
DNA (Bolotin et al., 2009, Lou et al., 2014). It is possible that some NRs could have 
shown high-affinity binding to other spacer lengths if different sequences had been used 
in the starting sequence of the spacers. 
Due to space limitations, I was also unable to include seed and SNV sets for other 
half-site arrangements (IRs, EREs, and DRs at longer spacer lengths), all of which have 
been shown to be utilized by NRs. My custom-designed PBM contained many IR, ERE 
and DR6-9 probes, which were intended to be used to clarify which NRs could utilize 
these alternative site structures. However, on our DR seed and SNV probes we 
unexpectedly found that high-affinity binding occurs via a half-site mode even on sites 
designed as DRs. This meant that for sites designed as IRs, EREs, and longer DRs the 
binding we measured may have been occurring via a half-site mode and might not require 
the full IR, ERE, or DR-sites. For this reason, analysis of these probes was excluded from 
my thesis. Further studies utilizing a different custom-designed PBM would be necessary 
to determine the importance of these binding sites.  
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While space was a limiting factor on this custom-designed PBM, from the outset 
of this project we intended to generate PWM models of binding affinity as they remain 
the prevailing model used to represent protein-DNA interactions. PWMs assume 
statistical independence between positions across a sequence and as such exhaustive 
combinatorial sampling of all possible sequences is not necessary to generate these types 
of models. 
2.6.2 Rationale and limitations of reporter assay experimental design 
Eukaryotic gene transcription is complex process that is dependent on TFs 
recognizing specific DNA sequences across the genome (Smale, 2001; Evans and 
Mangelsdorf, 2014). An outstanding problem in understanding TF biology and gene 
regulation is to understand the relationship between TF binding and TF function (Evans 
and Mangelsdorf, 2014). The simplest model to explain TF function at any given TF 
binding site would be a direct correlation between the affinity of a TF for a given DNA 
binding site and the amount of transcript produced from that binding site. To test the 
hypothesis that transcriptional output correlates with TF binding-site strength, we chose 
to use luciferase reporter assays using a vector containing a 3x repeat for each given test 
DNA sequence with 20 bp of intervening sequence between each repeat. The sequence 
context of these binding-sites was held constant (i.e, the spacing sequences used between 
the 3x repeats were the same for all test sequences). This configuration does not mimic a 
genomic environment; however, it is the clearest way to explicitly test for a correlation 
between NR binding-site strength and transcriptional activity, as it allows us to control 
for other variables that are known to influence gene regulation such as cooperative 
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binding with other TFs and chromatin context (Everett and Lazar, 2013). In the context of 
this experimental setup, a lack of correlation between binding-site strength and function 
suggests that higher-order models incorporating other parameters (e.g. ability to recruit 
coregulators) are required to model eukaryotic TF function on individual DNA binding 
sites, and suggests that binding site strength may not be an important parameter in models 
of TF function, other than perhaps to predict occupancy of a binding site at any given 
concentration of a TF.  
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Figure 2.1: Characterizing NR-DNA binding with PBMs.  
a Schematic of spacer preferences for NRs to direct repeats (DRs) and half-sites (HS). b 
Canonical spacer preferences of NRs indicate preferred spacer lengths from the literature (Table 
2.2). Published PWM models are shown in colored dots that indicate the methodology used to 
derive the model (List of models can be found in Supplementary Data 3 of (Penvose et al., 2019). 
c Schematic of PBM probes, SNV probe organization and SNV-based motif generation for a 
single seed sequence. d Scatter plot of z-scores for RARb:RXRa experiments detected with 
antibodies against each heterodimer partner. Dots represent average over ~5 replicates for all 
10,728 unique SNV probes (black dots) and 500 background probes (gray dots) e PBM replicate 
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averaged z-score distributions for PPARg:RXRa to all SNV probes. Z-scores for consensus DR1 
and reported functional binding sites are highlighted (Table 2.3)	(Juge-Aubry et al., 1997). f DR1 
DNA-binding logo for PPARg:RXRa generated from all DR1 full-site models from the PBM 
experiments. g Comparison of PPARg:RXRa PBM z-scores and competition EMSA-determined 
relative Kd measurements for binding sites spanning a wide affinity range. Relative Kd values are 
normalized to the highest affinity sequence (P1) and represent mean over two independent 
experiments (error bars = STDEV). Identifiable DR half-sites in each binding sequence are shown 
in bold. Mutations introduced to ablate the 5’ half-site of P3 (P3 5’Abl) or the 3’ half-site of P3 (P3 
3’Abl) are shown in red. Data and analysis by Ashley Penvose. 
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Figure 2.2: NR-binding specificity and DR preferences. 
PBM-derived DNA-binding logos for 12 NRs at all examined DR spacer lengths. To generate a 
logo, the seed sequence must have a z-score > 3.0; grey boxes indicate that none of the seed 
sequences met this threshold at that spacer length for that NR. For each NR at each spacer 
length or half-site, we show the average logo (average of individual logos generated from each 
seed sequence with z-score > 3.0 at that spacer length). Logos based upon a single significant 
(z-score > 3.0) seed sequence are indicated (∗). Data and analysis by Ashley Penvose. 
  
  
 
62 
 
Figure 2.3: NR half-site binding mode. 
a Schematic of NR full-site or half-site binding modes used by NRs to engage with DNA on the 
PBM. Faded protein and sequence indicates that the NR is not making base-specific contacts on 
the indicated half-site. b, c For three seed sequences bound with different modes, the impact of 
SNVs on LXRa heterodimer binding and the corresponding DNA-binding logos are shown. 
Binding perturbation for each SNV is shown as a Δz-score from the median z-score of all four 
base variants at each position. Colors correspond to base identity indicated in logos below. d 
DNA-binding logos for all 12 NRs generated for the single DR1 seed sequence shown. e Amino 
acid sequence of zinc finger 1 for the wild-type RXRa, RXRa DNA-binding domain mutant, wild-
type PPARg, and the PPARg DNA-binding domain mutant. Altered amino acids are highlighted in 
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gray. f DNA-binding logos for individual seed sequences (shown) for which the binding mode was 
either altered (left) or maintained (right) for the PPARg:RXRa-DNA binding domain mutant. Data 
and analysis by Ashley Penvose.   
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Figure 2.4: NR-binding affinity and mode for sequences at each DR spacer length.  
At each spacer length, the replicate averaged z-score of the highest scoring SNV for each seed 
sequence is shown; seed sequences with z-score < 3 are not represented. Colors indicate binding 
mode for each seed sequence. For each NR, box plots show the z-score distributions for all sites 
that are bound in half-site modes across all direct repeat spacer lengths (the aggregate of all gray 
dots). Center line: median; box limits: upper and lower quartiles; whiskers: last datum within 1.5x 
interquartile range. Data and analysis by Ashley Penvose.   
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Figure 2.5: NR specificity differences.  
a Scatter plots of LXRa and PPARg binding to DR1 and DR4 sites. Each spot is the average of ∼5 replicates for each unique DNA sequence (∼1600 at each spacer length) on the PBM. DR1 
and DR4 spacer-variant sequences are shown in the box below panel. b Binding logos generated 
for LXRa and PPARg for the spacer-variant seed sequences from a are shown. c Scatter plots as 
in 2.5a of VDR and PXR binding to DR1 and DR4 sites. d Scatter plots as in 2.5a of VDR and 
PXR binding to DR1 and DR3 sites. e Scatter plots as in 2.5a of LXRa and PXR binding to DR1 
and DR4 sites. f DR4 z-score logos, directly representing Δz-scores of SNV binding, are shown 
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for LXRa and PXR. Δz-scores are calculated (separately for each NR) as the difference from the 
median of all SNV variants. g Differential binding of NRs to spacer-sequence variants.  
(Top panel) Binding is shown for five NRs to the DR4 seed sequence  
5’-AGGTCATAGGAGGTCA-3’ and all 12 SNVs of the spacer region (spacer region in bold). Δ z-
scores are calculated as in 2.5f. (Bottom panel) Binding is shown for five NRs to the DR3 
sequence 5’-AGGTCAGAGAGGTCA-3’ and all nine corresponding SNVs of the spacer region 
(spacer region in bold). Examples of highly variant spacer sequences are indicated. Data 
generated by Ashley Penvose with this analysis performed by Trevor Siggers. 
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Figure 2.6: Genomic enrichment of NR-binding motifs.  
a Receiver-operating characteristic (ROC) curves for PPARγ motif enrichment in ChIP-seq data. 
ROC curves and area under the curve (AUC) values for different PBM-derived NR-binding 
models are shown, along with the results for best-performing published PPARγ DR1 motif 
(HOCOMOCO-f1, HMf1 (Kulakovskiy et al., 2013)). Motif enrichment for all models had p-
values < 10−46, using a Wilcoxon rank sum test with continuity correction and Bonferroni corrected 
for multiple hypotheses. b ROC curves for LXRα motif enrichment in ChIP-seq data. ROC curves 
and AUC values for different LXRα binding models are shown. Results for best-performing 
published LXRα DR4 motif (JASPAR MA0494.1 (Khan et al., 2018)) are shown. c ROC curves 
and AUC values are shown for PPARγ DR1 motif enrichment in reproducibly-bound PPARγ 
ChIP-seq peaks (solid lines, Methods), and for those peaks occurring within 10 kb upstream of 
differentially expressed genes (i.e., active peaks). d ROC curves and AUC values are shown for 
LXRα DR4 motif enrichment in reproducibly-bound LXRα ChIP-seq peaks (solid lines, Methods), 
and for those peaks occurring within 10 kb upstream of differentially expressed genes (i.e., active 
peaks). The data/models tested in this analysis were generated by Ashley Penvose. The genomic 
enrichment analysis was performed by Jessica Keenan. 
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Figure 2.7: Activity versus affinity for distinct classes of NR-binding sites.  
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a LXRa-dependent activity and binding affinity of a sequence bound in a half-site mode. 
Luciferase reporter gene activation, and corresponding z-scores, are shown for the DR1.7 
sequence, which is bound in a half-site mode on PBM, and sequences with each half-site ablated 
(DR1.17 and DR1.18), sequences shown in 2.7b. Fold-change reporter expression indicates 
luciferase activity in HEK293T cells over-expressing LXRa and RXRa normalized to cells not 
over-expressing these proteins. Fold-change expression is shown for cells treated with DMSO 
(vehicle), agonist (T0901317), or antagonist (GSK2033), and values represent mean over nine 
replicate measurements (error bars = SEM). Reporter gene p-values: * < 0.01, *** < 0.0001 
(calculated using Student’s two-tailed t-test). b Logo for LXRa heterodimer binding to DR1.7, and 
sequences for DR1.7, DR1.17, and DR1.18 discussed in 2.7a. c LXRa- and PPARg-dependent 
activity and PBM-derived binding scores to select DR1 and DR4 sites. Fold-change expression 
for LXRa is as described in a. Fold-change for PPARg is shown for cells treated with DMSO 
(vehicle), agonist (rosiglitazone), or antagonist (T0070907), and values represent the mean over 
nine replicate measurements (error bars = SEM). d Overview of relation between NR in vitro 
binding, in vivo binding, and function. Data and analysis by Ashley Penvose. 
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Supplementary figure 2.1: Comparison of NR homodimer and heterodimer binding.  
Z-scores for a the indicated NR as a heterodimer with RXR against the corresponding NR 
homodimer or for b RXR homodimer against the indicated NR homodimer. Dots represent 
average over ~5 replicates for all 10,728 unique SNV probes and 500 background probes. Data 
and analysis by Ashley Penvose.   
  
 
71 
 
Supplementary figure 2.2: Competition EMSA experiments for PPARg:RXRa 
a Representative EMSA gels of competition for binding by PPARg:RXRa to labeled DNA probe 
(P1, as described in Fig. 1g) and four unlabeled competitor DNA sequences whose sequence are 
shown in b. c Inhibition curves determined by quantifying the intensity of the bound probe band at 
different competitor concentrations for the different competitor experiments (error=STDEV, n = 2). 
Data and analysis by Ashley Penvose. 
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Supplementary figure 2.3: Impact of half-site ablation on LXRa binding.  
This analysis is similar to the analysis shown in Fig. 2.3, but is expanded to include all seed 
sequences for which z-score >3. For all seed sequences for which LXRa bound with z-score > 3, 
the box and whiskers plots of the z-score distributions of binding in full-site mode and each half-
site mode are shown, along with the corresponding 5’ or 3’ half-site ablations of each seed 
sequence. Center line: median; box limits: upper and lower quartiles; whiskers: last datum within 
1.5x interquartile range. Data and analysis by Ashley Penvose. 
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Supplementary figure 2.4: Impact of PBM probe orientation on NR binding logos. 
a DNA binding logos for RXRa homodimers and LXRa:RXRa are shown for DNA sequences 
bound in either a 5’ half-site or 3’ half-site binding mode. DNA binding logos were determined 
separately from PBM probes in which the binding site (and all SNVs used in the logo 
determination) are oriented in either the o1 or o2 orientation with respect to the glass slide 
(schematized in b ). Bases indicating the binding mode preference are highlighted with the red 
overlay box. b Schematic of DNA seed sequences used to generate the logos showing the 
orientation relative to the microarray glass slide. Data and analysis by Ashley Penvose in 
response to reviewer comments. 
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Supplementary figure 2.5: Impact of protein concentration on NR binding logos.  
a PPARg:RXRa DNA binding logos for DNA seed sequences bound in full or half-site binding 
modes are shown for PBM experiments performed at three different concentrations. The 
concentration of each monomer used in each PBM experiment is indicated. b The seed 
sequences for which the logos in a were generated. Identifiable DR half-sites in each binding 
sequence are shown in bold. Data and analysis by Ashley Penvose in response to reviewer 
comments. 
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Supplementary figure 2.6: DNA energy matrix logos for LXRa and PXR. 
DR1 and DR4 logos, directly representing Δ z-scores of SNV binding, are shown for LXRa and 
PXR. DR4 logos are derived from the same experiments as those in Fig. 5 and are shown for 
comparison. Positive Δ z-scores indicate z-scores higher than the median z-score for all base 
variants at that position. Data and analysis by Ashley Penvose. 
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Supplementary figure 2.7: DNA-shape parameters of spacer sequences for high and low-
affinity NR binding sites. 
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a Schematic of DNA seed sequences used to analyze DNA shape features (shown in b). Base 
positions in the spacer sequence between the DR half-sites are indicated in bold and referred to 
as B1,B2,B3 (DR3 site) and B1,B2,B3,B4 (DR4 site). Seed sequences were selected to represent 
diverse spacer sequences. b Distribution of DNA shape features for spacer sequences in either 
high-affinity sites (grey bars) or low-affinity sites (white bars). Data are shown for VDR and LXRa 
heterodimer binding experiments. For each of Supplementary figure 2.7: DNA-shape parameters 
of spacer sequences for high and low-affinity NR binding sites. For the 5 seed sequences (at 
each spacer length), we identified the two highest affinity and the two lowest affinity spacer 
sequence variants. Therefore, there are 10 (i.e, 5x2) high-affinity and 10 low-affinity spacer 
sequences considered for each bar plot. For each of the 10 spacer variants, DNA shape 
parameters were calculated at each base position using the TFBSshape server – major groove 
width (MWG), helix twist (HelT), propeller twist (ProT), and roll (Matys et al., 2006). Shown at 
each base position is the mean parameter over 10 sequences (error = STDEV). Distributions that 
were significantly different between the high and low-affinity sequences are shown (p-value 
calculated using a two-tailed t-test). Data was generated by Ashley Penvose. DNA shape 
analyses were performed by Trevor Siggers in response to reviewer comments.   
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Supplementary figure 2.8: Receiver operating characteristic (ROC) curves for PPARg and 
LXRa motif enrichment in ChIP-seq data. 
ROC curves for motif enrichment of PBM-derived PPARg-binding models are shown for all 
reproducibly-bound PPARg ChIP-seq peaks (dotted lines, a,c,e) and reproducibly-bound PPARg 
ChIP-seq peaks occurring within a 10 kb upstream, c 10 kb upstream or downstream, and e 50 
kb upstream of the transcription start site of differentially expressed genes (solid lines, Methods). 
ROC curves for motif enrichment of PBM-derived LXRa binding models are shown for all 
reproducibly-bound LXRa ChIP-seq peaks (dotted lines, b,d,e) and reproducibly-bound LXRa 
ChIP-seq peaks occurring within b 10 kb upstream, d 10 kb upstream or downstream, f and 50 kb 
upstream of the transcription start site of differentially expressed genes (solid lines, Methods). 
ROC curves determined using different PWMs for different DR and half-site (HS) modes are 
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indicated. The models tested in these analyses were generated by Ashley Penvose. The 
genomic enrichment analyses were performed by Jessica Keenan.   
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Supplementary figure 2.9: Impact of NR over-expression on reporter gene activity. 
a,b LXRa- and PPARg-dependent activity for the sequences described in Fig. 7 in the same 
treatment conditions. Shown separately are the luciferase activity values for the cells in which the 
NR:RXRa proteins were overexpressed (OE) and the values in which the proteins were not 
overexpressed (NoOE), each normalized to empty vector. Fold-change values in Fig. 7 are the 
ratio of these sets of values (i.e., OE/NoOE). Values represent the mean over nine replicate 
measurements (error bars = SEM). Data and analysis by Ashley Penvose. 
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Supplementary figure 2.10: Protein quality control for 
a,b SDS-PAGE of raw PPARg and RXRa overexpression lysate from E. coli and the fractions 
eluted after His-Tag purification of PPARg and RXRa. c,d SDS-PAGE and western blot of purified 
PPARg and RXRa. e,f Anti-His western blot of purified and IVT-produced PPARg, PPARg-
DBDmut, RXRa, and RXRa-DBDmut. Data and analysis by Ashley Penvose. 
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Supplementary figure 2.11: DNA binding activity test for purified proteins 
Purified His-tagged PPARg, LXRb, and RXRa were incubated with 1nM of 32P-labeled DNA probe 
in the presence or absence of 10x unlabeled competitor DNA of either the same sequence 
(specific competitor) or a different sequence to which the protein of interest should not show 
sequence-specific binding (non-specific competitor). Free probe and probe-protein complexes are 
indicated with arrows. Data and analysis by Ashley Penvose. 
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Supplementary figure 2.12: Quality control for purchased proteins 
Example Anti-His western blots of the purchased proteins that are listed in Table 2.1. Predicted 
molecular weight of each protein (kDa) is indicated in parentheses next to the protein name. Note 
1: The RARa and CAR samples shown here were not used on the PBM as they did not appear to 
be present at concentration reported by the manufacturer. A replacement sample of RARa was 
obtained and appeared to be the correct concentration. The manufacturer could not provide a 
replacement CAR protein. Note 2: The PPARb protein shown here was tested on PBM and did 
not show DNA binding activity. Data and analysis by Ashley Penvose. 
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Protein Source 
Product 
Number Tag 
Concentration used 
on PBM (nM) 
R2 of 
antibody 
replicates 
on PBM 
CAR 
Protein 
One P1096-01 His N/A N/A 
FXR 
Protein 
One P1044-01 His 270 0.95 
LXRɑ 
Protein 
One P1045-01 His 270 0.94 
LXRβ 
Protein 
One P1046-02 His 270 N/A 
LXRβ Abcam ab81924 His 270 0.93 
PPARɑ 
Protein 
One P1048-01 His 270 N/A 
PPARɑ Abcam ab81925 GST 270 0.97 
PPARb 
Protein 
One P1049-01 His 270 N/A 
PPARγ Isoform 
1 
Purified in 
our lab N/A His 180*** 0.98 
PPARγ Isoform 
1 
Protein 
One P1050-01 His 270 0.97 
PXR 
Protein 
One R1082-02 His 270 0.91 
RARɑ 
Protein 
One P1054-01 His 270 0.94 
RARβ 
Protein 
One P1056-01 His 270 0.98 
RARγ 
Protein 
One P1055-02 His 270 0.92 
RXRɑ 
Purified in 
our lab N/A 
Cleaved    
His 
90(Heterodimer)*** 
180(Homodimer)*** 0.98 
RXRɑ 
Active 
Motif 81082 His 90*** 0.97 
THRɑ 
Protein 
One P1052-02 His 90*** 0.97 
VDR 
Protein 
One R1084-2 His 270 0.91 
RXRɑ wild-type 
IVT in our 
lab N/A His 90* 0.98 
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RXRɑ DBDmut 
IVT in our 
lab N/A His 90* 0.89 
PPARγDBDmut 
IVT in our 
lab N/A His 270 N/A 
PPARγ wild-
type 
IVT in our 
lab N/A His 270 0.84 
Table 2.1 Sources and concentrations for proteins used in all experiments 
All proteins used were generated from human coding sequences. *** Indicates that a concentration other 
than 270 nM was used in this experiment. A value of N/A for the protein concentration or R2 of antibody 
replicates means that the proteins did not pass quality control checks by western blot or DNA binding activity 
experiments. 
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Response Element Sequence (5’à3’) Site Type NR Source 
CAAAACTAGGTCAAAGGTCA DR1 PPAR Juge-Aubry 1997 
ACAGTTCATGAAGTTCATC DR1 CAR, PXR Xie 2000 
CAAAACTAGGTCAAAGGTCACCTGC DR1 PPAR (all) Juge-Aubry 1997 
AAAAACTGGGCCAAAGGTCTCAGAA DR1 PPAR (all) Juge-Aubry 1997 
CAAATATAGGCCATAGGTCAGTGAT DR1 PPAR (all) Juge-Aubry 1997 
TGAAACTAGGGTAAAGTTCAGTGAG DR1 PPAR (all) Juge-Aubry 1997 
CAAATGTAGGTAATAGTTCAATAGG DR1 PPAR (all) Juge-Aubry 1997 
GCATTCTGGGTCAAAGTTGATCCCC DR1 PPAR (all) Juge-Aubry 1997 
ACTCCCACGGCCAAAGGTCATGAGA DR1 PPAR (all) Juge-Aubry 1997 
CTGAACTAGGGCAAAGTTCACCTGC DR1 PPAR (all) Juge-Aubry 1997 
CACAACTGGGATAAAGGTCTCGCTG DR1 PPAR (all) Juge-Aubry 1997 
GGGGACCAGGACAAAGGTCACGTTC DR11 PPAR (all) Juge-Aubry 1997 
GCGTTACAGGACAAAGGCCACCGAG DR1 PPAR (all) Juge-Aubry 1997 
TCTTACTGGATCAGAGTTCACTAGT DR1 PPAR (all) Juge-Aubry 1997 
AGGGCGCTGGGCAAAGGTCACCTGC DR1 PPAR (all) Juge-Aubry 1997 
GAGAGCAAGGTAGAAGGTCAAGAAA DR1 PPAR (all) Juge-Aubry 1997 
GTCTTTCAGGGCAACAGTCACATGC DR1 PPAR (all) Juge-Aubry 1997 
TCTCTCTGGGTGAAATGTGCATTTC DR1 PPAR (all) Juge-Aubry 1997 
GTGTTAGAGGGCACAGGTCCAGTGG DR1 PPAR (all) Juge-Aubry 1997 
CAACTAGGTCATCAGGTCA DR2 PPARɑ Juge-Aubry 1997 
GCTTCAGAACACCAGGAGAACAGAGAG DR5mut RAR Umesono 1991 
AGGTGAACAGGAGGACA DR5mut RAR Umesono 1991 
AGGTGAGGCTGCGGTGA DR5mut RAR Umesono 1991 
TTAAGGGTTCACCGAAAGTTCACTCGC DR5 RAR Umesono 1991 
GCTTCAGGTCACCAGGAGGTCAGAGAG DR5 RAR Umesono 1991 
AGGTCACCAGGAGGTCA DR5 RAR Umesono 1991 
AGGTGAACAGGAGGTCA DR5 RAR Umesono 1991 
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GGTTCACCGAAAGTTCA DR5 RAR Umesono 1991 
AGGTCACTGACAGGGCA DR5 RAR Umesono 1991 
GGGTCATTCAGAGTTCA DR5 RAR Umesono 1991 
TAAGGTCAATCCGAAGTCACTC DR5 RAR Umesono 1991 
TAAGGTCAAGCAGTGGTCCCTC DR5 RAR Umesono 1991 
TAAGGTCAATAAGGGGTGACTC DR5 RAR Kurokawa 1993 
TAAGGTCAAGGAAAGGACAATC DR5 RAR Kurokawa 1993 
TAAGGTCAACGATAGGGCACTC DR5 RAR Kurokawa 1993 
TAAGGTCAACATAGGGTCTCTC DR5 RAR Kurokawa 1993 
TAAGGTCAAAGGGCGGACACTC DR5 RAR Kurokawa 1993 
GGTAGGGTTCACCGAAAGTTCACTCGA DR5 RAR Kurokawa 1993 
CTTAAGGTCAACGGGTGGGCACTCAG DR2 RAR Kurokawa 1993 
CTTAAGGTCAAGAGTTCAATCCTCAG DR2 RAR Kurokawa 1993 
CTTAAGGTCAAAAGGTCGTTGCTCAG DR2 RAR Kurokawa 1993 
CTTAAGGTCAAAAGTTGACGCCTCAG DR2 RAR Kurokawa 1993 
TAGCTAGGTAAGATCAGGTAAGTAGC DR4 RAR & THR Umesono 1991 
GGGTAAGGTCACAATAAGGTCACGAAG DR5 THR Kurokawa 1993 
GCTGGAGGTGACAGGAAAACAGCAAG DR4mut THR Umesono 1991 
GCTGGAAATGACAGGAGGACAGCAAG DR4mut THR Umesono 1991 
GCTTCAGAACACAGGAGAACAGAGAG DR4mut THR Umesono 1991 
TGGTCACAGGTGGTCA DR4mut THR Umesono 1991 
AGGTAAGATCAGGTAA DR4mut THR Umesono 1991 
GGGTGAATGGGGGTGA DR4mut THR Umesono 1991 
GGTTCACCGAAGTTCA DR4mut THR Umesono 1991 
AGCTGGGGTTAGGGGAGGACAGTAAG DR4 THR Umesono 1991 
GCTGGAGGTGACAGGAGGACAGCAAG DR4 THR Umesono 1991 
GCTGGAGGTGACGAAAGGACAGCAAG DR4 THR Umesono 1991 
GCTCAGGGTCATTTCAGGTCCTTGAA DR4 THR Umesono 1991 
GCTTCAGGTCACAGGAGGTCAGAGAG DR4 THR Umesono 1991 
AGGTCACAGGAGGTCA DR4 THR Umesono 1991 
AGGTGACAGGAGGTCA DR4 THR Umesono 1991 
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AGGTGACAGGAGGACA DR4 THR Umesono 1991 
GGGTTAGGGGAGGACA DR4 THR Umesono 1991 
GGGTCATTTCAGGTCC DR4 THR Umesono 1991 
GGGCCAGCTGAGGTTA DR4 THR Umesono 1991 
AAGGGGATCCAGCTTCAGGTCACAGGAGGT
CAGAGAGCT DR4 THR Meier 1993 
GGGTAAGGTCAAATAAGGTCACGAAG DR4 THR Kurokawa 1993 
TCTGGAGGTGACAGGAGCACAGCGGA DR4 THR Kurokawa 1993 
TGATCAGGTCATCAGGTCACAGAT DR2 THR Kurokawa 1993 
GCTTCAGAACAAGGAGAACAGAGAG DR3mut VDR Umesono 1991 
AGGTCAGCTAGGTTA DR3mut VDR Umesono 1991 
GCTTCAGGTCAAGGAGGTCAGAGAG DR3 VDR Umesono 1991 
AGGTCAAGGAGGTCA DR3 VDR Umesono 1991 
GGGTGAATGAGGACA DR3 VDR Umesono 1991 
GGGTGAACGGGGGCA DR3 VDR Umesono 1991 
GGTTCACGAGGTTCA DR3 VDR Umesono 1991 
Table 2.2 Literature curated response elements  
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Response Element Sequence (5’à3’) Label in figure 
CAAAACTAGGTCAAAGGTCA Fig1e-Consensus 
TGAAACTAGGGTAAAGTTCAGTGAG Fig 1e-High Affinity DR1 
ACTCCCACGGCCAAAGGTCATGAGA Fig1e-Medium Affinity DR1 
GAGAGCAAGGTAGAAGGTCAAGAAA Fig1e-Low Affinity DR1 
Table 2.3 DR1 sequences with EMSA-derived affinity ranks used as controls on PBM 
Note: All sequence were obtained from (Juge-Aubry et al., 1997)  
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DNA sequence (5’à3’) 
DR site 
type Label in figure 
GCCAAACTAGGTCAAAGGTCAAAGTCGAGCCAACCA DR1 Fig 1g- P1 
GCTCTAGTTGGTCAAAGGTCACACACTCGAAATGCG DR1 Fig 1g- P2 
GCTCTTGTAGATCAAAGGTTAAGAAAGCCGAAGCCT DR1 Fig 1g- P4 
GCTATACAGGGTCAAAGGCCAGAGTACGAATGTCGA DR1 Fig 1g- P3 
GCTATACACCGTCAAAGGCCAGAGTACGAATGTCGA DR1mut Fig 1g- P3 5'Abl 
GCTATACAGGGTCAAAGGCGAGAGTACGAATGTCGA DR1mut Fig 1g- P3 3'Abl 
GCCCAGACAGGTGAAAGGTAACTCAGTCTGGTACGC DR1 Fig 1g- P5 Abl 
GCTCTTGTAGATCAGCAGGCTGAGAAAGCTGGCCAA none Fig 1g- P6 
Table 2.4 DNA sequences from PBM used for competition EMSA experiments 
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DNA Sequence (5’à3’) 
Site 
Type Label in figure 
GCTCTAGTTGGTCAAAAGTCACACACTCGAAATGCG DR1 Fig 7-DR1.1 
GCTCTAGTTGGTCAAAGGTCACACACTCGAAATGCG DR1 Fig 7-DR1.3 
GCCGTCCAAGGTCACAGGTCAGTGAAGAGATGACGG DR1 Fig 7-DR1.4 
GCTGTCAAAGTTCAAAGGTAACGTAAGTATCCACAC DR1 Fig 7-DR1.7 
GCCAAACTAGGTCAAAGGTCAAAGTCGAGCCAACCA DR1 Fig 7-DR1.8 
GCTGTCAAAGTTCAAAGGTAGCGAAAGTATCCACAC HS 
Fig 7-DR1.17, 3’ ablation of 
DR1.7 
GCTGTCAATCTTCAAAGGTAACGTAAGTATCCACAC HS 
Fig 7-DR1.18, 5’ ablation of 
DR1.7 
GCCAAACTAGGTCACGAAAGGTCTAAGTCGAATGAC DR4 Fig 7-DR4.10 
GCCAAACTAGGTCACGAAAGGTCAAAGTCGAATGAC DR4 Fig 7-DR4.11 
GCCCTACTGGGCCACGAAAGGTCATTGATTCAGTGA DR4 Fig 7-DR4.12 
GCTCTTGTAGATCAGCAGGCTGAGAAAGCTGGCCAA N/A 
Insert for “empty vector” to mimic 
sequence context of test element 
inserts. Used for normalization to 
“empty vector” 
Table 2.5 DNA sequences used in reporter elements 
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 DR0 DR1 DR2 DR3 DR4 DR5 
Seed 1 AAACTAGGTCAAGGTCAAAGT
C 
A AG CAG CGAA CCGGA 
Seed 2 CTAGTTGGTCAAGGTCACACA
C 
A GG CGG GCTG GTAAA 
Seed 3 CTCGGAGGACAAGGTCAGAGC
T 
A GA CGA CGAA ACAGG 
Seed 4 CTACTGGGCCAAGGTCATTGA
T 
A TC AAA CGAA TTCAG 
Seed 5 CTTACGGGTCAAGGTTATAGC
A 
A CG ACG CTCC CTGAC 
Seed 6 CTAGCAGGCCAGGGTCACTCA
A 
A GA TTT ATCT AGTTT 
Seed 7 CATATAGGTAAAGGTGAAAGT
C 
A AC TAC TACA ATGCT 
Seed 8 CTTGTAGATC AGGTTAAGAA
A 
A GC AGC ATAG ACAGG 
Seed 9 TCTCTAGGTAAAGTTCAGTGA
A 
A CA CCA AGAT GACTC 
Seed 10 
1010 
TCGAAAGGTCGAGGTGAGTAT
A 
A TG ACG GTTG TGCTC 
Seed 11 CTATTAGTTG AGGGCAACCG
A 
A TT CTT GACG CCATA 
Seed 12 CGACTGGGGC AGGTTACCAT
A 
A TA GAA AAGC TCAGC 
Seed 13 GTCCAAGGTC AGGTCAGTGA
A 
A GC GAG TAGG ATGCT 
Seed 14 CTGCTAGGTCATGGTCAGCTA
A 
A GT GGT ACGA ACTGA 
Seed 15 GAACTAGGTC AGGACAGTGA
A 
A CC TCC GAAC TTGAC 
Seed 16 AGCCTAGGTC GGGCCAGTAT
A 
A TT TGC GATC TTCAG 
Seed 17 TATGTAGGTT GGGTCATTCA
G 
A TC AGG GCTG CATCC 
Seed 18 ATACAGGGTC AGGCCAGAGT
A 
A CT GCT TCGT GCTAG 
Seed 19 CAGACAGGTGAAGGTAACTCA
G 
A GA TGA GTGA AACGA 
Seed 20 GAATGAGGTT AGATCAGGGA
A 
A TA TTA CCAA TACGT 
Seed 21 GTCAAAGTTCAAGGTAACGTA
A 
A CT TCT ACTA GGACG 
Seed 22 TACCAAGGTG AGGTCGTTGA
T 
A AT ACA GCTG eTCGTG 
Seed 23 GAACGAGGGC AGTTGATAGC
A 
A TG ATG TTCG CGCTG 
Seed 24 CGAGTAGGTTAGGGGCATTCA
G 
A CG GTC CGAG CCAAT 
 Table 2.6 DNA seed sequences for custom-designed NR PBM  
Shown are the 24 starting seed sequences with no intervening spacer bases (DR0) and the bases of the 
spacer sequence that was inserted between the two half-sites to create the corresponding seed at longer 
spacer lengths (DR1-5). For each seed, the first half-site of the DR is highlighted in red and the second half-
site of the DR is in blue. The 5 nt of each the 5’ and 3’ flanks are shown in black. On the PBM, SNV probes 
of the seed sequences shown above were included across the entire region shown. 
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NR Assay 
FXR PBM  
LXRa PBM, Luciferase reporter, Genomic enrichment analyses 
LXRb PBM  
PPARa PBM  
PPARg PBM, competition EMSA, PBMs with DBDmut proteins, Luciferase reporter, 
Genomic enrichment analyses 
PXR PBM  
RARa PBM  
RARb PBM  
RARg PBM  
RXRa PBM, PBMs with DBDmut protiens 
THRa PBM  
VDR PBM  
Table 2.7 Summary of assays done on each nuclear receptor 
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CHAPTER THREE: TYPE II NR DNA BINDING SPECIFICTY AND 
COREGULATOR RECRUITMENT FROM NUCLEAR LYSATE 
All experiments were performed by Ashley Penvose. 3T3-L1 cell culture and 
differentiation for some samples was performed by Stephanie Kim from the lab of 
Jennifer Schlezinger at Boston University Medical School. Data analysis, figures, and 
writing by Ashley Penvose as advised by Trevor Siggers.  
3.1 Abstract 
In Chapter 2, I characterized the binding of purified type II NRs and demonstrated 
that most NRs bind with high affinity to many different DR spacer lengths. This finding 
disagrees with the prevailing model in which NRs exhibit binding preferences for a 
particular DR spacer length. However, using reporter gene assays, I also demonstrated 
that NR-dependent gene expression is mediated by binding sites that conform more 
closely to canonical models of NR DR-spacer preference. These observations suggest that 
(1) NR-DNA binding is promiscuous, but NRs can only regulate gene expression when 
bound to select DR sites, and/or (2) NR-DNA binding in cells is more specific than was 
observed with purified proteins. To test this second hypothesis, I utilized nextPBM to 
measure NR binding from 3T3-L1 adipocyte nuclear lysate. I observe high-affinity 
binding of RXRα-containing complexes to a broad range of DR spacer lengths (DR0-5). 
Interestingly, I find that the binding preferences of PPARγ from nuclear lysate are altered 
compared to purified PPARγ:RXRα, and better recapitulate the previously reported 
  
 
95 
preference for DR1 binding. To explore the possibility that DNA sequence may act as an 
allosteric regulator of coregulator assembly and NR function, I measured the recruitment 
of SRC1 from 3T3-L1 adipocyte nuclear lysates with nextPBM. I find that SRC1 
recruitment shows strong DNA specificity to sites that resembles a NR half-site, but also 
show an extended sequence preference for the 3 bases that are 5’ of the NR-like half-site. 
3.2 Introduction 
Nuclear receptors (NRs) are a large family of ligand-activated transcription 
factors (TFs) that serve as key regulators of development, metabolic homeostasis, 
inflammation, and protection from xenobiotics (Evans and Mangelsdorf, 2014). NRs rely 
on sequence-specific DNA binding to regulate their target genes (Evans and 
Mangelsdorf, 2014). NRs bind the sequence 5’-RGKTCA-3’ organized as direct repeats 
(DRs) with a variable length spacer of 0–5 base pairs (bp) (DR0-DR5) (Weikum et al., 
2018). Previous studies had suggested that each NR has distinct DNA binding 
preferences for certain DR spacer lengths, which enable individual NRs to distinguish 
their target genes (Juge-Aubry et al., 1997; Umesono et al., 1991). However, our recent 
work demonstrated that purified NRs bind with high affinity to many different DR spacer 
lengths, and have largely overlapping binding specificity (Penvose et al., 2019). Using 
reporter assays, I also found that canonical DR spacer preferences better predict NR 
function than NR binding (Penvose et al., 2019). These observations suggest that (1) NR-
DNA binding is promiscuous, but NRs can only regulate gene expression when bound to 
select DR sites, and/or (2) NR-DNA binding in cells is more specific than was observed 
with purified proteins. 
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Recruitment of coregulatory proteins (CoRs) to TFs is an essential step in 
transcriptional regulation (Rosenfeld and Glass, 2001). Preferential assembly of distinct 
transcriptional complexes at different regulatory loci is thought to underlie locus-specific 
transcriptional responses (Zhang and Verdine, 1999). Previous work has shown that DNA 
can act as an allosteric regulator of co-regulator assembly for the NRs (Hall et al., 2002) 
and that allostery can impact NR function (Meijsing et al., 2009).  
As key sensors of metabolic state and regulators of metabolic gene programs, 
NRs are central to the function of adipocytes (Jacobi et al., 2012). Highlighting the 
importance of NRs in adipocyte function, PPARγ is a master regulator of adipogenesis 
and is both necessary and sufficient for the conversion of pre-adipocytes into mature 
adipocytes (Rosen et al., 1999). Many NRs (30 of 49) are expressed in 3T3-L1 
adipocytes including PPARβ and γ, LXRα and β, TRα and β, RARα, β, and γ, and RXRα, 
β and γ (Fu et al., 2005). As such, 3T3-L1 adipocytes represent an ideal cell-type to study 
NR-DNA binding specificity in a cellular context. 
To test whether NR-DNA binding preferences are altered in a cellular context, we 
performed nextPBM experiments using nuclear lysate from 3T3-L1 adipocytes to 
measure the binding of NRs. We are able to capture high-affinity binding of RXRα-
containing complexes to a broad range of DR spacer lengths (DR0-5). Interestingly, we 
find that the binding preferences of PPARγ from nuclear lysate are altered compared to 
purified PPARγ:RXRα, and better recapitulate the previously reported preference for 
DR1 binding (Juge-Aubry et al., 1997). To explore the possibility that DNA can act as an 
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allosteric regulator of coactivator recruitment, we measured SRC1 recruitment from 3T3-
L1 nuclear lysate on nextPBM. I find that SRC1 recruitment shows strong DNA 
specificity that resembles a NR-like half-site with extended sequence preferences for the 
3 bases 5’ of the NR-like half-site. 
3.3 Results 
3.3.1 Measuring NR binding from 3T3-L1 lysate 
Our recent work, in which we characterized the binding of purified type II NRs 
(Penvose et al., 2019), demonstrated that most NRs bind with high affinity at many 
different DR spacer lengths (Penvose et al., 2019). This finding disagrees with the 
prevailing model in which NRs exhibit binding preferences for particular DR spacer 
length (e.g., that PPARg binds preferentially to DR1 sites) (Evans and Mangelsdorf, 
2014; Palmer et al., 1995). To test whether NR binding in a cellular context is different 
than for purified proteins, I analyzed NR binding using our recently described nuclear 
extract protein binding microarray (nextPBM) approach (Mohaghegh et al., 2019), which 
measures TF binding using nuclear lysates instead of purified samples to better simulate 
the cellular environment. NextPBM has the advantage of querying TF binding in a cell-
type specific context that accounts for endogenous post-translational modifications, and 
the presence of other transcription factors and coregulators (CoRs) that may alter the 
binding landscape of transcription factors. I used nextPBM to measure NR binding from 
3T3-L1 adipocyte nuclear lysates (schematized in Fig. 3.1a).  
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To examine type II NR binding by nextPBM, I utilized the same PBM microarray 
design that we used previously to characterize the binding of purified type II NRs 
(Penvose et al., 2019). Briefly, this PBM design contains over 1600 unique sequences at 
each of six DR spacer lengths (DR0-DR5). For each DR spacer length, I measured NR 
binding to 24 starting sequences, which we refer to as seed sequences (Fig. 2.1c). Seed 
sequences were generated by combining different half-site sequences exhibiting a range 
of degeneracy from the consensus 5’-RGKTCA-3’ (Penvose et al., 2019). I also measure 
binding to all single-nucleotide variants (SNVs) of each seed sequence. This SNV-based 
design allows me to generate binding models for each seed sequence (described in detail 
in (Penvose et al., 2019)). 
To gain a broad picture of the NR binding landscape from 3T3-L1 adipocyte 
lysate, I performed nextPBM experiments using an antibody against RXRα, which allows 
me to detect binding of complexes containing RXRα, including RXRα homodimers and 
all type II NRs as heterodimers with RXRα (schematized in Fig. 3.1b). To quantify 
binding specificity, nextPBM fluorescence values were converted into z-scores using a 
set of 500 random genomic sequences (Methods 3.5.4). We observe high specificity NR 
binding over a range of affinities, up to a z-score of 12 (Fig. 3.1c). Comparing 
independent biological samples of 3T3-L1 adipocytes, I observe strong agreement in 
binding of RXRα (Fig. 3.1d, R2=0.93). These results demonstrate that using nextPBM I 
can reproducibly capture high specificity binding of RXRα complexes from nuclear 
lysates generated from 3T3-L1 adipocytes. 
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To examine the broad DNA-binding preferences of RXRα complexes from 3T3-
L1 adipocyte nuclear lysate, we examined which DR spacer lengths are bound with high-
affinity by RXRα complexes. We detected high-affinity binding of RXRα to all DR 
spacer lengths examined, DR0-5 (Fig. 3.1e). In our previous study of purified NR 
heterodimers (Penvose et al., 2019) we used a SNV modeling approach (Andrilenas et al., 
2018; Penvose et al., 2019) to generate binding logos. The SNV approach allowed us to 
define the binding mode of the NR dimers to each individual DR seed site. Using this 
same approach I annotated the binding mode of RXRα dimers to all high-affinity sites as 
either full-site (i.e., both DR half-sites are engaged) or half-site (i.e., only a single DR 
half-site is engaged). I observe that almost all high-affinity RXRα binding events in our 
assay occur via a full-site binding mode, and that there appears to be an enrichment of 
high-affinity binding to DR1 and DR4 sites (Fig. 3.1e, blue dots). Examining the binding 
logos generated for our highest affinity DR sites at each spacer length (e.g., DR0-5), I 
observe base preferences consistent with the canonical 5’-RGKTCA-3’ half-site 
preferences we previously defined using purified NR proteins (Fig. 3.1f). These results 
demonstrate that in 3T3-L1 adipocyte extracts there are RXRα dimers capable of binding 
with high-affinity to all DR spacer lengths (DR0-5) in a full-site mode.  
3.3.2 NR binding landscape is altered in a cellular context 
PPARγ is a key regulator of differentiation and maintenance of adipocytes, with a 
reported preference for DR1 DNA binding sites ( Palmer et al., 1995, Juge-Aubry et al., 
1997). To examine whether PPARγ from 3T3-L1 adipocyte lysates (PPARγ-AL) exhibit 
the same promiscuous DNA-binding preferences that I observed for purified 
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PPARγ:RXRα, I performed nextPBM experiments using 3T3-L1 adipocyte nuclear 
lysates and an antibody against PPARγ. A DNA binding logo generated for PPARγ-AL 
binding to a DR1 sequence recapitulates the known base preferences for binding across 
the DR1, and captures the previously reported preference for the sequence 5’-ACT-3’ 
upstream of the DR-site (Fig. 3.2a) (Juge-Aubry et al., 1997), demonstrating that my 
nextPBM experiments accurately capture PPARγ dimer binding specificity.  
To examine the PPARγ-AL binding specificity landscape more broadly, I 
compared the full binding profiles (i.e., across all DR sites) of purified PPARγ:RXRα 
(Penvose et al., 2019) and PPARγ-AL (Fig. 3.2b). PPARγ-AL showed a lower dynamic 
range of binding than that of purified PPARγ:RXRα, likely due to a lower concentration 
of PPARγ in the lysate samples and/or to competition with other NRs for dimerization 
with RXRα. To avoid any complications arising from the different dynamic ranges, I 
chose to only consider sequences that were bound by purified PPARγ:RXRα with high-
affinity (z-score > 7, Fig. 3.2b blue and light blue) in subsequent analyses, as this is also 
the inflection point at which PPARγ-AL shows binding above background. At any given 
affinity for purified PPARγ:RXRα, the binding of PPARγ-AL spans a broad range of 
affinities. For example, for sites bound by purified PPARγ:RXRα with a z-score ~10 
(Fig. 3.2b, red rectangle), PPARγ-AL binds over a range of affinities, from a z-score of -
0.3 to 9.1. Strikingly, many sites bound with high affinity by purified PPARγ:RXRα are 
bound with low affinity by PPARγ-AL (Fig3.2b, light blue dots).  
The binding data for purified PPARγ:RXRα dimers was generated for human 
protein sequences expressed and purified from E.coli. The species of the expression host 
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is known to impact protein folding and post-translational modifications that may affect 
protein function (Structural Genomics Consortium et al., 2008).To test whether the 
alteration in binding that I observe in Fig. 3.2b is due to differences between bacterial and 
mammalian expression systems, I measured the binding of PPARγ:RXRα purified from 
HEK-293T cells, a mammalian cell line of human origin, and compared it to the binding 
of PPARγ:RXRα purified from E. coli. I found strong agreement in binding of 
PPARγ:RXRα from both expression hosts (Fig. 3.2c, R2 = 0.90), suggesting that the 
binding differences observed between purified and lysate samples are not due to the 
means of protein expression. 
To determine if the differences in PPARγ binding observed between purified and 
lysate samples are a general phenomenon occurring on all DNA sequences, or whether 
they are specific to certain DR spacer lengths, I compared the binding affinity of PPARγ-
AL to at each spacer length. I focused my analysis on sequences bound with high affinity 
by purified PPARγ:RXRα (z-score > 7, Figure 3.2b, dark and light blue dots). The 
binding of PPARγ-AL was significantly different across the different spacer lengths (Fig. 
3.2d, p < 0.0001 by one-way ANOVA on ranks). PPARγ-AL showed a strong preference 
for high-affinity binding only to DR1 sites (Fig. 3.2d, p < 0.0001 by Dunn’s Test for all 
comparisons to DR1). Binding was also significantly different across spacer lengths for 
purified PPARγ:RXRα, (Fig. 3.2e, p < 0.0001 by one-way ANOVA on ranks). In contrast 
to PPARγ-AL, purified PPARγ:RXRα had a significant preference for binding to both 
DR1 and DR4 sites (Fig. 3.2e, see figure for individual comparisons). For purified 
PPARγ:RXRα, the preference for specific spacer lengths were not as strong as the 
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preference seen in PPARγ-AL (comparing figure 3.2d and 3.2e). DR1 sites are the 
canonically reported spacer preference for PPARγ (Evans and Mangelsdorf, 2014; 
IJpenberg et al., 1997; Palmer et al., 1995), and are enriched in ChIP-seq experiments 
measuring in vivo binding of PPARγ (Nielsen et al., 2008; Siersbaek et al., 2012). This 
refinement in the DR spacer preferences of PPARγ-AL supports the hypothesis that the 
DNA binding-site preferences of NRs is altered, and becomes more specific, in the 
presence of the full complement of soluble nuclear components. 
3.3.3 SRC-1 is recruited to DNA in a sequence-specific manner 
To test whether the disconnect between NR binding and activity might also be a 
result of selective recruitment of CoRs to specific DNA sites, I examined how CoR 
recruitment by NRs correlated with NR binding. We have recently extended the 
nextPBM methodology to measure recruitment of CoRs to DNA-bound TFs. NextPBM 
experiments are performed using nuclear extract from cells, which contains both TFs and 
CoRs. By utilizing an antibody for the CoR of interest, we are able to detect indirect 
recruitment of CoRs to DNA-bound TFs (schematized in Fig. 3.3a). Furthermore, using 
our SNV-based approach described for generating NR binding logos, we can determine 
CoR recruitment logos, which are analogous to TF binding logos but directly reflect 
binding the specificity of the larger multi-protein TF-CoR complex.  
The steroid receptor coactivators (SRCs) are CoRs of NR function, serving as 
scaffolds to recruit other CoRs and to bridge NRs to the basal transcriptional machinery 
(Johnson and O'Malley, 2012). SRC1 knockout mice show increased obesity due to a 
decrease in energy expenditure, positioning SRC1 as a key coregulator of adipocyte 
  
 
103 
function (Picard et al., 2002). Over the course of adipogenesis in 3T3-L1 adipocytes, 
SRC1 expression increases dramatically (Picard et al., 2002). SRC1 has been shown to be 
recruited to many NRs including PPAR, FXR, THR, and RXR (Dowell et al., 1997; Kim 
et al., 1999; Treuter et al., 1998; Wang et al., 2018b). For these reasons, I chose SRC1 for 
my pilot experiments of CoR recruitment from 3T3-L1 adipocyte lysate. 
I measured the recruitment of SRC1 from 3T3-L1 adipocyte lysate using 
nextPBM. As SRC1 is recruited by RXRα-containing complexes, I anticipated that SRC1 
recruitment profiles and RXRα binding profiles would be highly similar. Surprisingly, I 
observe distinct DNA binding/recruitment profiles, as can be seen by the lack of 
correlation between the measured SRC1 and RXRα profiles (Fig. 3.3b). For sites that 
bind RXRα with high-affinity, SRC1 shows a range of recruitment, from a z-score of -2 
up to a z-score of 6, demonstrating that SRC1 is not recruited well by all 
RXRα−containing complexes (Fig. 3.3b, blue box). In contrast, SRC1 is also recruited 
with high-affinity to sites that show weak RXRα binding (Fig. 3.3b, red box), suggesting 
that SRC1 is recruited by TFs other than RXRα-containing complexes. SRC1 is known to 
be recruited to other NRs, including the estrogen related receptors (ERRs) and hepatocyte 
nuclear factor 4 (HNF4), which also bind to the DR-sites that are prevalent on this 
custom-designed PBM (Albers et al., 2005). Further experiments will be needed to 
determine if SRC1 recruitment is occurring to these other NRs.  
As CoRs rely on specific interactions with TFs for recruitment to DNA, logos of 
CoR recruitment represent the binding preferences of the TF-CoR complex. Our SNV 
approach gives us the unique advantage of modeling binding for a single DNA seed 
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sequence, which enables us to observe any changes in TF binding preferences induced by 
CoRs as alterations in the recruitment logos (eg. allosteric changes in TF binding can be 
observed as changes in recruitment logos). Comparing the logos obtained for SRC1 to 
those for RXRα on the same seed sequence, I see distinct DNA binding preferences for 
these two factors (Fig.3.3c). On all of these seeds, RXRα binds to full DRs, making 
sequence specific contacts with both half-sites (Fig. 3.3c, bottom row of logos, grey 
shading indicates half-sites of the DR seed). SRC1 logos reflect general NR binding 
preferences (i.e., 5’-RGKTCA-3’ sites); however, in contrast to the RXRα logos, SRC1 
recruitment logos demonstrate that recruitment occurs in many different modes, both to 
half-sites and full DRs (Fig. 3.3c, top row of logos, grey shading indicates half-sites of 
the DR seed). The strong similarity of binding preferences seen in the SRC1 recruitment 
logos and NR binding logos indicates that SRC1 is likely being recruited to DNA by a 
NR. However, these altered base preferences suggest that either these SRC1-NR 
complexes do not contain RXRα, or that SRC1 interaction induces an altered DNA-
binding specificity to the RXRα-containing complex, constituting a form of allosteric 
regulation of SRC1 recruitment.  
Examining SRC1 logos (Fig. 3.4) in detail, I observe distinct sequence features 
underlying SRC1 recruitment, extending beyond the core NR-like half-site(s). A strong 
preference for an A in the position immediately 5’ of the NR-like half-site is seen in all 
SRC1 recruitment logos (Fig. 3.4, red box). For some seed sequences, strong sequence 
preferences for SRC1 recruitment are also seen in logos at positions more 5’ of the NR-
like half-site, with a preference for C or T in the position 3 nucleotides upstream of the 
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NR-like motif and for G or C in the position 2 nucleotides upstream of the NR-like motif 
(Fig. 3.4c, black box). These recruitment preferences hold true for all logo types 
(extended 5’ half-site, extended 3’ half-site, or extended full-site), with the extended 
binding preferences always occurring 5’ of the NR-like half-site. In the case of an 
extended full-site, these preferences are seen in the 5’-flanking sequence of both half-
sites (Fig. 3.4, black and red boxes of extended full DRs, column 3 of logos). These 
findings suggest that SRC1 is preferentially recruited to DNA sequences with specific 
sequence features, which may arise from recruitment to specific NRs, recruitment of 
CoRs only to NRs bound to DNA with a certain sequence composition (eg. allosteric 
recruitment), or both.  
3.4 Discussion 
Recent work from our lab demonstrated that purified NRs display a broader DNA 
binding specificity than had previously been described in the literature (Penvose et al., 
2019). Additionally, we demonstrated that models that conform to the canonically 
reported spacer preferences for NR are more enriched in ‘functional binding’ events from 
ChIP-seq data (Penvose et al., 2019). Based on these findings we hypothesized that NR 
binding may be altered in a cellular context. To test this, I used nextPBM to measure the 
binding of NRs from 3T3-L1 adipocyte nuclear lysate. To address whether CoR might 
also be selectively recruited by NRs to specific sequences, in a novel extension of the 
nextPBM platform, I also measured recruitment of the NR coregulator, SRC1. 
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I found that the binding preferences of PPARγ from nuclear lysate are altered 
compared to the binding of purified PPARγ:RXRα. PPARγ from lysate preferentially 
binds to DR1s, in agreement with both the in vitro and in vivo binding preferences 
previously reported by many others (Fu et al., 2005; Juge-Aubry et al., 1997); however, 
the high-affinity binding to DRs of many spacer lengths that we reported for purified 
PPARγ:RXRα (Penvose et al., 2019) suggests that this preference is not purely 
determined by DNA binding affinity. The factors that lead to the alteration in binding 
seen between purified and lysate PPARγ remain unclear. Additionally, the extent to 
which the binding landscape of other NRs is altered in nuclear lysate requires further 
investigation.  
3T3-L1 cells are a fibroblast cell line derived from mice (Kassotis et al., 2017) 
The DNA binding preferences of the type II NRs presented in Chapter 2 of this thesis 
were measured using proteins that were expressed from human coding sequences; 
however, I do not believe this alteration in binding is likely to be attributed to species-
dependent differences in DNA binding. PPARg is highly conserved in mice and humans, 
sharing complete amino acid identity within the DBDs and differing by only 9 amino 
acids total for PPARg1 (Pap et al., 2016). Additionally, their reported DNA binding 
preferences are highly similar, (Chandra et al., 2008; Soccio et al., 2015). To 
experimentally confirm that the altered PPARg in nuclear lysate from 3T3-L1s is not a 
species-specific difference in DNA binding preferences, I could perform nextPBM 
experiments using nuclear lysate from a cell line of human origin. Alternatively, the 
easiest experiment to interpret would be one in which I co-incubated 3T3-L1 adipocyte 
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nuclear lysate with His-tagged human PPARg and RXRa and detected binding of PPARg 
using an antibody for the His-tag. If the same alteration in binding preferences was 
observed in this experiment, it would suggest that some component of the nuclear lysate 
alters the binding preferences of PPARg. 
An additional complication in interpretation of the alteration in binding 
preferences of PPARg -AL is the multiple isoforms of PPARg present in 3T3-L1 
adipocytes. 3T3-L1 adipocytes express both PPARg1 and PPARg2 isoforms (Desvergne 
and Wahli, 1999). The PPARg2 isoform arises from alternative splicing, and is expressed 
highly only in adipocytes (Desvergne and Wahli, 1999). PPARg2 encodes for an 
additional 28 (human) or 30 (mouse) amino acids at the N-terminus of the protein as 
compared to the PPARg1 isoform. The PPARg antibody used in these experiments 
recognizes both the PPARg1 and g2 isoforms. It is possible that the PPARg2 isoform of 
the protein has different DNA binding preferences than the PPARg1 isoform used in 
purified protein experiments. The spike-in experiment with His-tagged PPARg and 
RXRa proposed above to test species-specific PPARg binding preferences would also 
allow us to avoid complications in interpreting the data that may arise from any isoform-
specific DNA binding preferences for PPARg.  
I found that SRC1 is preferentially recruited to DNA sequences with a distinct 
base composition. This finding suggests that either 1) SRC1 is only recruited to certain 
NRs, or 2) SRC1 is only recruited to NRs bound to DNA with certain sequence features 
(e.g. allosteric recruitment to DNA). These interpretations are not mutually exclusive, 
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and both are supported by existing evidence. In support of the first interpretation, SRC1 
is known to recruit strongly to only a subset of NRs. Existing evidence supporting the 
second interpretation includes the allosteric recruitment of coregulators that has been 
seen for other NRs, including ER, GR, and VDR (Koszewski et al., 2000; Meijsing et al., 
2009; Schöne et al., 2016). Further experiments will be required to distinguish these two 
possible interpretations of preferential SRC1 recruitment.  
Few methodologies exist to measure and model CoR recruitment in a high-
throughput manner. As TFs rely on interactions with CoRs to mediate their function, 
using the nextPBM to measure CoR recruitment offers the potential to create and test 
models of functional TF binding.  
3.5 Materials and Methods 
3.5.1 3T3-L1 Culture and Differentiation 
NIH 3T3-L1 (ATCC: CL-173) pre-adipocytes were maintained in pre-adipocyte 
media (high-glucose DMEM with 10% calf serum, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 0.25 µg/ml amphotericin B). Cells were passaged when they reached 
~70-80% confluence, approximately every 3 days. Before inducing adipogenesis, cells 
were grown as above until they reached confluence, about 4 days from plating. To induce 
adipogenesis, the medium was replaced with DMEM containing 10% fetal bovine serum 
(FBS) (Sigma-Aldrich), 250 nM dexamethasone, 167 nM human insulin, 0.5 mM 
isobutyl methyl xanthine, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells were 
treated with either vehicle (dimethyl sulfoxide (DMSO), 0.1% final concentration) or 
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rosiglitazone (20 µM, Cayman Chemicals). On days 3 and 5 of differentiation, the 
medium was replaced with adipocyte maintenance medium (DMEM with 10% FBS, 167 
nM human insulin, 100 U/ml penicillin, and 100 µg/ml streptomycin), and the cultures 
were supplemented with either vehicle or rosiglitazone. On Day 7 of differentiation, 
medium was replaced with adipocyte medium (DMEM, 10% FBS, 100 U/ml penicillin, 
100 µg/ml streptomycin), and the cultures were supplemented with either vehicle or 
rosiglitazone. On day 10 after the initiation of differentiation, nuclear lysates were 
harvested as described below. 
3.5.2 Nuclear extract preparation 
Differentiated 3T3-L1 adipocyte cells were scraped from flasks in ice cold PBS. 
When cells were grown in T75 flasks, three flasks were combined and processed as a 
single sample using the protocol below. If using T225 flasks, each flask was processed 
individually as a single sample. All volumes given in the protocol below are for a single 
sample. Cells were pelleted at 500 x g for 5 min at 4°C in a 15 ml conical tube. The pellet 
was resuspended and washed with 10 ml of PBS and pelleted at 500 x g for 5 min at 4°C. 
To remove residual salt remaining from the PBS buffer, the cells were resuspended in 1 
ml of low salt buffer (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl with 1 µl 
protease inhibitor cocktail (Sigma-Aldrich, cat # P8340) and 1 mM DTT), transferred to a 
1.5 ml tube, and pelleted immediately at 500 x g for 5 min at 4°C. The cell pellet was 
resuspended in 1 ml of low-salt buffer and incubated for 10 min on ice. Fifty µl of 5% 
IGEPAL (Sigma-Aldrich, cat # I8896) was added to the cell suspension and vortexed for 
10 sec. Cells were incubated for an additional 10 min on ice. Nuclei were pelleted at 
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750 × g for 5 min at 4°C. The supernatant was removed from the nuclear pellet and saved 
as the cytosolic fraction. To remove residual cytosolic proteins from the surface of the 
nuclear pellet, 100 µl of the low-salt buffer was gently pipetted onto the side of the tube 
and allowed to wash the pellet, with care taken not to disrupt the nuclear pellet. This 
wash was then gently removed and combined with the cytosolic fraction. Next, 200 µl of 
high-salt buffer (20 mM HEPES (pH 7.9), 25% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, 
420 mM NaCl with 1 µl protease inhibitor cocktail and 1 mM DTT) was pipetted on the 
pellet and vortexed for 30 s followed by nutation at 4°C for 1 h. The nuclei were pelleted 
at 4°C for 20 min at 21,000 × g. The supernatant was transferred into a new 1.5 ml tube 
and labeled as the nuclear soluble protein fraction. Protein concentration of the nuclear 
lysate was quantified using the Pierce Coomassie Bradford Plus reagent (Pierce) 
following the manufacturer’s microplate protocol. From either 3-T75 flasks or a single 
T225 flask, I typically obtained lysate at a concentration of ~4-5 mg/ml with a total 
protein yield of ~ 0.8 -1.0 mg. Nuclear lysate samples were aliquoted into single use 
samples and snap frozen in liquid nitrogen and stored at -80°C until use. 
3.5.3 PBM custom design 
PBM experiments were performed using custom-designed microarrays (Agilent 
Technologies Inc. AMADID 084387, 4 × 180 K format). PBM probes contain a 24 nt 
constant primer region, a 34 nt variable region, and a 5’ GC dinucleotide cap (probe 
sequences can be found in Supplementary Data 4 of (Penvose et al., 2019)). For each 
unique SNV probe sequence, five replicate probes were included in each orientation (10 
probes per unique sequence). For all other probe sequences four replicate probes were 
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included with the 34 nt variable region in each orientation (8 probes per unique 
sequence). 
SNV probes: DR seed sequences, defined by two 6-bp half-sites and a variable 
spacer (0–5 bp), were aligned within the 34 nt variable region of each PBM probe. For 
each seed sequence, SNV probes were created that had a single-nucleotide variant at each 
position of the DR half-sites, the spacer sequence between the DR half-sites, and in the 
5 bp flanks of each site. Therefore, for a single 13 bp DR1 site (i.e., 6 + 6 + 1 = 13), 
including 5 bp flanks on either side, there would be 69 (i.e., 23 × 3) unique SNV probe 
sequences. 
Random genomic probes: 34 nt regions were randomly chosen from the UCSC 
hg19 build of human genome. Sequences were removed that contained Ns or single-
nucleotide repeats longer than three nucleotides. 
3.5.4 NextPBM Experiments 
Double stranding – Microarrays were double-stranded as previously described 
(PBM double-stranding primer 5’-CCTTCATTCTACGCTGTCAATCGC-3’) (Berger 
and Bulyk, 2009; Berger et al., 2006b). 
Blocking – All wash steps were carried out in coplin jars on an orbital shaker at 
125 rpm. Double-stranded DNA microarrays were first pre-washed in PBS containing 
0.01% Triton X-100 (5 min), rinsed in a PBS bath, and then blocked with 2% milk in 
PBS for 1 hour. Following the blocking step, arrays were washed in PBS containing 0.1% 
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Tween-20 (5 min), then in PBS containing 0.01% Triton X-100 (2 min), and finally 
briefly rinsed in a PBS bath.  
Protein binding – Arrays were next incubated with the protein sample (purified 
protein or 3T3-L1 nuclear lysate) for one hour in a binding reaction buffer containing: 
2% milk (final concentration); PBS pH 7.4; 1 mM DTT; 0.2 mg/ml BSA; 0.02% Triton 
X-100; and 0.4 mg/ml salmon testes DNA (Sigma D7656). For nuclear lysate samples, 
the final concentration of total protein in the protein binding mixture was 2.0 mg/ml in a 
volume of 180 µL. Concentrations of purified proteins used for PBM experiments can be 
found in Table 2.1.  
Primary antibody – Microarray sandwiches were disassembled in PBS containing 
0.05% Tween-20 (3 min) and then de-wetted in plain PBS. Microarrays were then 
incubated with 20 µg/ml of primary antibody in 180 µL of 2% milk in PBS for 20 min. 
Primary antibodies used were anti-PPARγ antibody (Abcam ab41928), anti-RXRa 
(Active Motif 61029), and anti-SRC1 (Abcam ab2859). 
Secondary antibody - Microarray sandwiches were disassembled in PBS 
containing 0.05% Tween-20 for 3 min and then de-wetted in plain PBS. Microarrays 
were then incubated with 20 µg/ml of Alexa488-conjugated secondary antibody or 
Alexa647-conjugated secondary antibody in 180 µL of 2% milk in PBS for 20 min. 
Excess antibody was removed by washing with PBS containing 0.05% Tween-20 for 3 
min and then PBS for 2 min.  
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PBM data analysis - Microarrays were scanned with a GenePix 4400A scanner 
and fluorescence was quantified using GenePix Pro 7.2. Exported data were normalized 
using MicroArray LINEar Regression (Berger et al., 2006b). Microarray probe sequences 
and fluorescence values from each experiment are provided (See Supplementary Data 4 
of (Penvose et al., 2019)). NR dimers exhibit an orientation-specific bias in our PBM 
experiments; therefore, data from probes in a single orientation (i.e., ‘_o1′ probes in 
Supplementary Data 4 of (Penvose et al., 2019)) was used in our final analysis. However, 
all results were observed for probes in both orientations and models from each orientation 
showed good agreement. 
DNA-binding logos were generated using the previously described SNV-based 
approach (Andrilenas et al., 2018; Penvose et al., 2019). 
3.6 Limitations of the nextPBM platform 
3.6.1 Competition for RXR as a partner 
In both in vitro and in vivo assays when multiple NRs are present in a mixture, 
NRs compete for dimerization with RXR as a partner (Miyata et al., 1996, Tobin et al., 
2000, Chan and Wells, 2009). Decreased binding of LXR/RXR is observed in EMSAs 
when PPAR is added to the binding reaction (Tobin et al., 2000). In cells, overexpression 
of PPAR leads to a dose-dependent decrease in expression of an LXR-regulated reporter 
gene expression (Tobin et al., 2000). In cells that are overexpressing PPAR, co-
immunoprecipitation of RXR with LXR is reduced as compared to cells in which PPAR 
is not overexpressed (Tobin et al., 2000). In all cases, these effects are not seen when 
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supplemental RXR is provided, suggesting that limiting quantities of RXR underlie these 
observations, rather than direct competition for DNA binding (Tobin et al., 2000). 
Considering these findings, it is likely in the mixture of proteins from nuclear 
lysate used on nextPBM, we are observing competition amongst NRs for RXR as a 
dimeric partner; however, this competition does not explain why the decrease in DNA 
binding of PPARg from lysate is DR spacer-length dependent. In other words, if the 
decreased binding of PPARg in lysate is a consequence of the effective concentration of 
the PPARg:RXR heterodimer due to competition for RXR as a partner, one would expect 
that sites that are bound with equal affinity by the purified heterodimer would show a 
uniform decrease of PPARg:RXR binding from lysate, which is not what I observed. 
Therefore, while competition for RXR as a partner is a factor that must be considered 
when interpreting nextPBM results, other factors are likely contributing to the altered 
binding preferences of PPARg.  
3.6.2 Competition for DNA binding sites 
An alternative explanation for the altered DNA binding preferences of PPARg 
from lysate observed on nextPBM could be that multiple NRs in the lysate are competing 
for binding on certain DNA sequences. Competition for binding to DRs has been reported 
by other groups (Chan and Wells, 2009). However, I do not think that the PPARg-AL 
binding preferences I found by nextPBM are explained by competition for DNA binding 
sites. Our lab has tried to directly measure competition on the PBM using purified 
proteins at concentrations higher than those of the NRs in lysate and we were unable to 
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detect competition (e.g., the binding profiles obtained for the individual NRs were the 
same as those when the NRs were co-incubated on the array). This lack of competition 
for DNA binding sites is likely explained by the high concentration of DNA on the PBM, 
though the exact amount of DNA at any given array spot is proprietary information that 
the manufacturer (Agilent) does not publicly disclose.  
3.6.3 Multiple NR isoforms and isotypes present in cells 
NRs exist as different isoforms, and multiple isoforms are expressed in a single 
cell-type, such as the 3T3-L1 adipocytes for the experiments in this chapter. For instance, 
as discussed in Section 3.4, PPARg is present in 3T3-L1 adipocytes in both the g1 and g2 
isoform. It is possible that different isoforms have distinct DNA binding preferences. 
Additionally, humans and mice each contain three paralogous genes for RXR (a, b, and 
g) (Desvergne and Wahli, 1999). In NR biology, the paralogs of individual NRs are 
commonly referred to as isotypes (Desvergne and Wahli, 1999). PPARg is able to 
dimerize with any of the three RXR isotypes. RXR isotypes serve partially redundant 
functions, but are not entirely able to compensate for one another. For instance, 
adipocyte-selective knock-out of RXRa leads to impaired induction of lipogenic gene 
programs and resistance to obesity in mice; however, this effect is not seen in RXRg-null 
mice (Metzger et al., 2005). Additionally, adipocyte formation is not impaired for 
adipocyte-selective knock-out of RXRa nor in RXRg-null mice, but is impaired in 
adipocyte-selective knock-out of RXRa in RXRg-null mice (Metzger et al., 2005). The 
presence of similar isoforms and isotypes of NRs in cells complicates the interpretation 
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of nextPBM binding data as different isoform and isotype dimers may have distinct 
binding preferences, and the current approaches used to measure binding do not delineate 
between distinct isoform and isotype complexes (e.g., when individually measuring the 
binding of PPARg, we can look at the correlation of binding of RXRa at the same probes 
to infer the heterodimeric partner, but it is possible that PPARg forms heterodimers with 
all the RXR isotypes. This makes it difficult to attribute the binding observed on 
nextPBM experiments to a single PPARg:RXR heterodimer, hence making it more 
difficult to directly compare the binding preferences to a single purified protein complex. 
Despite this, nextPBMs still represents a way for us to capture the binding preferences of 
TF complexes in a context that more closely resembles a cellular context.  
3.6.4 Antibody selection for nextPBM experiments  
One of the greatest technical challenges with the nextPBM is finding antibodies 
that perform well in nextPBM experiments. Antibodies are considered “good” on 
nextPBM when experiments show a broad dynamic range of signal and the models 
generated show sequence-specificity (e.g., the models resemble existing models or are 
reproducible). As a starting point, whenever possible, we use antibodies that are ChIP-
grade, as these antibodies have been shown to recognize native protein when bound to 
DNA and to selectively recognize their target protein within a complex mixture of 
proteins. In cases where no ChIP-grade antibodies are available, we choose antibodies 
that have been demonstrated to work in assays where the protein is in a native 
conformation, such as EMSA supershift or immunoprecipitation experiments. Even with 
this initial selection step, we still find that many antibodies do not perform well on 
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nextPBM, either giving low overall signal or showing poor specificity (e.g., high 
background). Failure of antibodies to perform well in nextPBM experiments may be due 
to a variety of factors including epitope masking, lack of expression of the protein of 
interest in the lysate, background binding to DNA alone, and/or binding to non-target 
proteins. 
Even for antibodies that perform well on the nextPBM, a variety of factors could 
influence interactions of the antibody with its target protein. This may be a more 
pronounced problem in nextPBM experiments as compared to PBM experiments using 
purified proteins, as masking of the epitope recognized by the antibody is more likely to 
occur in lysate due to factors such as the potential PTMs present on the protein and 
interactions with coregulators that occlude portions of the TF. It is also possible that the 
epitope that the antibody recognizes may be inaccessible due to structural changes of the 
TF when binding certain DNA probes; or that DNA-induced structural changes in the 
protein may change the affinity of the protein-antibody interaction on some probes. In the 
case of CoRs, certain antibodies may disrupt TF-CoR interactions. These complications 
highlight the importance of supporting any findings on nextPBM using orthogonal 
methodologies.  
Despite the complications presented here, the nextPBM methodology offers a 
novel way to measure and model protein-DNA and coregulator-protein-DNA interactions 
in an environment that better simulates a cellular context.  
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Figure 3.1: NR binding from 3T3-L1 adipocyte nuclear lysate examined by nextPBM   
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a Schematic overview of NextPBM experiment using 3T3-L1 adipocyte nuclear lysate.  
b Schematic demonstrating that a single RXRa antibody allows assessment of binding for all 
RXRa-containing complexes. c PBM replicate averaged z-score distributions for RXRa-
containing complexes from 3T3-L1 adipocyte nuclear lysate for all SNV probes (blue) and 
genomic background probes (grey). d Scatter plot of z-scores of binding for two independent 
biological replicates for RXRa-containing complexes from 3T3-L1 adipocyte nuclear lysate. Dots 
represent average over ~5 replicates for all 10,728 unique SNV probes (black dots) and 500 
background probes (gray dots). e At each DR spacer length, the replicate averaged z-score for 
each seed sequence is shown; seed sequences with z-score < 3 are not represented. Colors 
indicate model-type for each seed sequence. f Representative logos from seeds at each DR 
spacer length. For each logo, the 5’ half-site is boxed in grey and the 3’ half-site is boxed in red. 
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Figure 3.2: PPARγ binding landscape from 3T3-L1 adipocyte nuclear lysate   
a Logos for purified PPARg:RXRa and PPARg from 3T3-L1 adipocyte nuclear lysate bound to a 
DR1 seed. Grey boxes indicate each half-site of the direct repeat within the seed. b Scatter plot 
comparing z-scores for PPARg from 3T3-L1 adipocyte nuclear lysate to purified PPARg:RXRa on 
all SNV probes. Colors represent classification of probes as high-affinity (dark and light blue dots) 
or low-affinity (grey dots) for purified PPARg:RXRa. c Scatter plot comparing z-scores of binding 
of PPARg:RXRa purified from 293T cells and PPARg:RXRa purified from E. coli. Dots represent 
average over ~5 replicates for all 10,728 unique SNV probes (black dots) and 500 background 
probes (gray dots). d, e At each DR spacer length, the distributions of z-scores of binding for 
PPARg from 3T3-L1 adipocyte nuclear lysate (3.2d) or purified PPARg:RXRa (3.2e) are shown. 
Data are shown only for probes bound by purified PPARg:RXRa with a z-score >7.0. Center line: 
median; box limits: upper and lower quartiles; whiskers: last datum within 1.5x interquartile range.  
Differences in binding to certain spacer lengths were tested by one-way ANOVA by ranks 
followed individual comparisons using Dunn’s test with correction for multiple hypothesis testing. 
n.s denotes no significant difference, ** denotes p < 0.01, **** denotes p < 0.0001 as calculated 
by Dunn’s test with correction for multiple hypothesis testing. 
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Figure 3.3: Measuring SRC1 recruitment from 3T3-L1 adipocyte nuclear lysate. 
a Schematic overview of NextPBM experiment using 3T3-L1 adipocyte nuclear lysate to measure 
coregulator recruitment. b Scatter plot of z-scores of binding of SRC1 and RXRα-containing 
complexes from 3T3-L1 adipocyte nuclear lysate. Dots represent average over ~5 replicates for 
all 10,728 unique SNV probes (black dots) and 500 background probes (gray dots). Red box 
indicates high-affinity SRC1 binding and low affinity RXRα binding. Blue box indicates the range 
of SRC1 recruitment occurring to sites that RXRα binds with high-affinity. c Representative logos 
of RXRα binding and SRC1 recruitment determined using the same seed and SNV sequences. 
Grey highlights indicate half-sites within each probe sequence. Red boxes indicate flank 
sequences of SRC1 recruitment that show distinct base preferences compared to RXRα.  
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Figure 3.4: SRC1 shows distinct DNA sequence preferences for recruitment 
Logos of SRC1 recruitment on different seed sequences. Grey highlight indicates the half-sites 
within each probe sequence. Red and black boxes indicate flank sequences of SRC1 recruitment. 
DR(2-5) indicates the design of the seed probe. 
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Antibody Source Species Epitope NextPBM notes 
LXRb Abcam 
ab56237 
Rabbit Synthetic peptide 
corresponding to Human 
LXRb aa 37-86 
Medium signal and good 
specificity 
PPARg Abcam 
ab41928 
Mouse Baculovirus-expressed 
recombinant fragment, 
corresponding to amino acids 
3-105 of Human PPARg 1+2.  
Good signal and specificity 
RXRa Active Motif 
61029 
Mouse Recombinant protein 
corresponding to C-terminal 
region of RXRa 
Good signal and specificity 
RIP140 Abcam 
ab42126 
Rabbit Recombinant protein 
corresponding to C-terminal 
region of RIP140 
Low overall signal 
SRC-1 Abcam 
ab2859 
Rabbit Synthetic peptide 
corresponding to Human 
KAT13A/ SRC1 aa 8-24. 
Good signal and specificity 
SIRT1 Millipore   
07-131 
Rabbit GST-tagged fusion protein 
corresponding to amino acids 
1-131 of mouse SIRT1 
Low overall signal 
TBL1X Santa Cruz 
sc-365661X 
Mouse specific for an epitope 
mapping between amino acids 
119-148 within an internal 
region of TBL1X of human 
origin 
Low overall signal 
 
Table 3.1: Antibodies tested in nextPBM experiments using 3T3-L1 adipocyte nuclear lysate 
Shown are the antibodies that I have tested in nextPBM experiments using 3T3-L1 adipocyte nuclear lysate. 
The source and species host of the antibody are listed. The manufacturer’s notes on the epitope within the 
protein that is recognized by the antibody is shown. The nextPBM notes column indicates the performance 
of the antibody in nextPBM experiments. 
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CHAPTER FOUR: DISCUSSION/ FUTURE DIRECTIONS 
4.1 Summary and future directions 
The goal of the research presented in this thesis was to explore the determinants 
of regulatory specificity for the type II NRs. At the time we began this work, existing 
PWM models of NR binding were not able to uniquely discriminate the genomic targets 
of NRs. Additionally, DNA had been shown to be an allosteric regulator of CoR 
recruitment; however, few studies had examined this phenomenon using a high-
throughput approach, and this phenomenon had only been studied for a limited set of 
NRs. In this research, I used PBMs to measure the DNA binding preferences of 12 
purified type II NRs. In a follow-up to this work with purified NRs, I used nextPBM to 
measure binding of NRs from nuclear lysate, and to measure recruitment of SRC1 in the 
presence of DNA. 
In Chapter 2 of this thesis, I demonstrated that the binding preferences of purified 
NRs do not conform to their previously reported DR-spacer preferences. Discrepancies 
between our findings and previously reported preferences may result from the different 
approaches used to establish these preferences. Previous studies that broadly examined 
the DNA binding preferences of NRs used EMSAs to test DNA binding affinity. The test 
sequences used were either semi-random oligonucleotide pools, coupled to multiple 
rounds of PCR to enrich the DNA sequences to which the NR was bound (Kurokawa et 
al., 1993; Näär et al., 1991), which leads to enrichment for only the highest affinity 
binding sites and does not capture the full range of NR binding; or were derived from 
ligand-responsive genes (IJpenberg et al., 1997; Palmer et al., 1995) for the NR in 
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question, thus biasing the results toward functional NR binding. Additionally, binding 
affinity in EMSA is estimated from the amount of DNA probe that is shifted in the 
presence of the TF of interest, which requires that the TF-DNA complex remains 
assembled throughout the electrophoretic process, and as such may not accurately capture 
equilibrium binding (e.g., sequences for which TFs show comparable affinity (Kd) but 
different kon and koff rates may not result in the same amount of shifted probe). An 
advantage to our PBM approach was the ability to directly compare NR DNA binding 
preferences on thousands of different DNA sequences at multiple different spacer lengths 
(DR0-5). Additionally, our SNV modeling approach enables us to create models for 
individual DNA sequences, allowing for a greater understanding of NR-DNA interactions 
than was previously possible. 
A novel finding of Chapter 2 was the widespread high-affinity binding of NRs to 
half-site sequences. Half-site binding has been reported for other TFs, including GR and 
NF-kB (Siggers et al., 2011; Weikum et al., 2017). GR binding in the promoters for pro-
inflammatory genes had long been reported to occur through indirect recruitment to 
another TF, AP-1; however, a recent study demonstrated that recruitment to these sites is 
not dependent on AP-1, but rather is mediated through direct GR-DNA interactions that 
occur through binding to GR half-sites that are imbedded within AP-1 binding sites. 
Similarly, homodimers of c-Rel, a member of the NF-kB TF family, bind with high 
affinity to NF-kB half-sites to preferentially activate distinct gene targets (Siggers et al., 
2011). These findings demonstrate that half-site binding occurs for other TFs that 
normally function as dimers and highlights the importance of these half-sites in gene 
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regulation. Further work will be required to delineate the functional importance of half-
site binding for the type II NRs.  
In Chapter 2, we also demonstrated that canonical DR spacer preferences for an 
individual NR are enriched in ‘functional’ genomic binding data for that NR, and 
correlate with function of that NR as measured in reporter assays. The strong correlation 
of canonical spacing preferences with NR function may have reinforced the binding 
preferences for NRs that had been established by EMSA. The findings from Chapter 2 
suggest that in cells (1) NR binding preferences are altered by some unknown 
mechanism(s) and/or (2) NRs can bind more broadly than these canonical rules would 
suggest, but they mediate transcription only from DRs of certain spacer lengths.  
This disconnect between TF binding affinity and TF function is seen for many 
other transcription factors (Andrilenas et al., 2018). Investigating the mechanisms 
underlying this disconnect remains difficult, as gene regulation is a multi-step process 
that is regulated at many levels. Furthermore, determining how these mechanisms, which 
may involve allostery, may differ between reporter assays and in vivo genomic binding is 
very complicated. However, we think that these types of integrative comparisons of TF 
DNA-binding affinity data and reporter gene assay data provide an initial starting point 
for understanding the relationship between TF binding and TF function that will highlight 
how pervasive these types of phenomena may be for different classes of TFs.  
In Chapter 3 of this thesis, I tested whether binding of NRs is altered in a cellular 
context by utilizing nextPBM to measure the binding preferences of NRs from 3T3-L1 
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adipocyte nuclear lysate. I observed high-affinity binding of RXRa-containing 
complexes to all DR spacer lengths examined (DR0-5). Strikingly, the binding of PPARγ 
from nuclear lysate showed altered binding preferences, with a strong preference for 
binding to the canonically reported DR1 site (Palmer et al., 1995). This finding is of 
particular interest as it raises questions about what mechanisms in a cellular context 
contribute to these changes in binding. Future nextPBM experiments should seek to 
determine if the binding preferences of other NRs are also altered in cell lysate. In 
nuclear lysate, interactions with coregulators may alter NR structure, destabilizing NRs 
on the “wrong” DR spacer, to refine their binding landscape. To test whether the binding 
landscape of NRs is altered by interactions with CoRs, the binding of purified NRs in the 
presence of CoRs could be measured by PBM. As many CoRs are quite large and the 
domains utilized by different TFs to interact with CoRs is often known, isolated domains 
of these proteins may make such experiments more tractable.  
Promoter-specific TF function has been demonstrated for a variety of TFs, 
including the NRs (Johnson and O'Malley, 2012); however, the mechanisms dictating 
such locus-specific function largely remain unclear. Allosteric coregulator recruitment, 
wherein DNA sequence impacts productive interactions with CoRs without impacting the 
DNA binding affinity of the recruiting TF, is one mechanism that could explain 
promoter-specific NR function. Allosteric regulation of coregulator recruitment provides 
a mechanism for decoupling TF DNA binding affinity from transcriptional activity, as 
sites not conforming to these preferences may show decreased CoR recruitment and 
decreased transcriptional upregulation. In section 3.3.3, I used nextPBMs to explore the 
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possibility that SRC1, a NR CoR, assembles only on a subset of NRs bound to DNA and 
that certain DNA sequence features can be associated with this recruitment. I found that 
SRC1 is differentially recruited to RXRα−containing complexes, with SRC1 being 
recruited strongly to some RXRα−containing complexes and not at all to others. 
Additional experiments will be required to determine if this finding represents allosteric 
recruitment of SRC1, binding of SRC1 to only a subset of NRs, or both.  
The ability of DNA to act as an allosteric regulator of TF function has been 
demonstrated by other groups for NF-kB and the glucocorticoid receptor (Meijsing et al., 
2009; Wang et al., 2012). Additionally, previous studies have demonstrated that allosteric 
recruitment of CoRs influences NR function (Meijsing et al., 2009). Genomic analyses 
using models of SRC1 recruitment generated from nextPBM experiments will allow us 
test whether SRC1 recruitment preferences better predict functional NR binding in the 
genome as compared to models of NR binding alone (similar to the analyses performed in 
Section 2.3.8, however, models of SRC1 recruitment would be utilized rather than 
models of NR binding).  
Additionally, DNA-based allosteric alteration of TF interactions with CoRs and 
subsequent impact on TF function may provide a mechanism to explain the impact of 
some single-nucleotide polymorphisms (SNPs) on gene regulation. Interest in precision 
medicine continues to increase as the decrease in cost of whole-genome sequencing 
makes it more feasible (Nielsen, 2017). The recent availability of large amounts of 
genomic data has led the identification of many disease-associated SNPs (Hindorff et al., 
2009). The majority of SNPs (>90%) do not fall within the sequence of genes, but rather 
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in noncoding regions of the genome that are often regulatory regions, such as promoters 
and enhancers; and the impact of these SNPs is not fully understood (Bryzgalov et al., 
2013; Hindorff et al., 2009). Regulatory SNPs have also been shown to correlate with 
responsiveness to treatment with rosiglitazone, a PPARγ ligand used to treat type II 
diabetes (Soccio et al., 2015). It is possible that for at least a subset of regulatory SNPs, 
the SNPs do not alter TF binding, but rather alter CoR recruitment, either leading to 
decreased or increased interactions with CoR that alter TF function at a SNP. The 
nextPBM provides a novel high-throughput platform to screen for both changes in TF 
binding and DNA-based allostery in the context of disease-associated SNPs.  
Utilizing the nextPBM platform, we are able to investigate many outstanding 
questions about how TFs function in a cellular context and interact with other proteins 
that may be important for their function. TF binding may be altered in a cellular context, 
due to signal-dependent PTMs or through cooperatively binding to DNA with other TFs; 
these types of changes can be measured in the nuclear lysate samples used on the 
nextPBM. Additionally, a large outstanding problem for understanding transcriptional 
regulation mediated by TFs is the ability to discriminate non-functional TF binding from 
functional TF binding. The majority of TF binding events measured by ChIP-seq appear 
not to serve a functional purpose (Spivakov, 2014); and the current models used to 
predict TF binding (such as PWMs) are unable to determine which binding events will 
have functional consequences (Evans and Mangelsdorf, 2014). The nextPBM provides a 
novel platform to measure and model TF-DNA interactions in an environment that more 
  
 
130 
closely mimics a nuclear context, and to measure and model the ability of TFs to form 
higher-order transcriptional complexes on specific DNA sequences. 
Our lab is also planning to use a modified form of massively parallel reporter 
assays (MPRA) to test and model TF function. In this technique, synthetic promoter 
sequences containing the test DNA binding sites of interest are coupled to a reporter gene 
and unique molecular identifiers (UMIs). These UMIs allow us to map the resulting 
transcripts back to the test DNA binding sites. Utilizing this modified MPRA, we can test 
the function of hundreds of DNA sequences (or more) in parallel. The test sequences in 
this modified MPRA will be designed from models of TF function derived from 
nextPBM experiments. This assay can be done in the presence or absence of 
overexpression of the TF of interest, to better enable us to attribute reporter gene 
expression to a specific TF. Modified MPRAs allow us to test models of functional TF 
binding generated by nextPBM in a functional assay.  
The goal of this thesis was to undertake research into the determinants of type II 
NR DNA-binding and gene regulatory specificity. This research has resulted in the 
generation of dozens more NR PWM models than were previously available, all of which 
can be used to predict NR binding in the genome. The promiscuous DNA binding 
preferences of the type II NRs and disconnect between NR DNA binding and NR gene 
regulatory function reveal the need for further investigation into the determinants of 
functional NR-DNA binding. The findings presented in chapter 3 suggest that DNA 
binding specificity of NRs are altered in nuclear lysate by some unknown mechanism and 
that DNA-based allostery may play a role in the recruitment of higher order complexes to 
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NRs. Further research should seek to clarify the determinants of functional NR binding, 
changes in NR DNA binding preferences in cells, and the molecular mechanisms 
underlying both of these phenomena.  
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